zoledronic acid has been researched along with Osteonecrosis in 288 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 143 (49.65) | 29.6817 |
| 2010's | 110 (38.19) | 24.3611 |
| 2020's | 35 (12.15) | 2.80 |
| Authors | Studies |
|---|---|
| Huo, L; Li, JW; Wang, JY; Yu, RQ; Zheng, LW | 1 |
| Errani, C; Marchetti, A; Massari, F; Mollica, V; Nigro, MC; Nuvola, G; Rizzo, A; Rosellini, M; Tassinari, E | 1 |
| Lemound, J; Otto, M; Weigel, J; Ziebart, T | 1 |
| Gwack, Y; Ho, K; Kim, RH; Kim, S; Kim, T; Lenon, A; Williams, DW | 1 |
| Andreis, JD; Castro, ML; Claudino, M; Delfrate, G; Fischborn, AR; Franco, GCN; Mecca, LEA; Mroczek, T; Oliveira, FB; Rigo, NM; Taba Junior, M | 1 |
| Fasciolo, A; Fusco, V; Gambino, A; Palmeri, S; Rossi, M | 1 |
| Neal, TW; Schlieve, T | 1 |
| Alves, K; Alves, NM; Brito, GAC; de Sousa, VC; Girão, V; Goes, P; Leitão, R; Lopes, AP; Martins, CS; Sousa, FRN; Vasconcelos, RF; Viana, D | 1 |
| Pazianas, M | 2 |
| Hokugo, A; Jewett, A; Kanayama, K; Kaur, K; Morinaga, K; Nishimura, I; Sun, Y | 1 |
| An, J; Chen, S; Dong, X; He, L; He, Y; Wang, J; Wang, X; Zhang, Y; Zheng, Y | 1 |
| Iijima, H; Imamura, M; Ito, K; Kumagai, M; Muro, Y; Shiraishi, Y; Yabusaki, R; Yoshimura, K | 1 |
| Cui, Y; Li, M; Luo, S; Yang, P; Zhang, W; Zhu, S | 1 |
| Kim, HS; Kim, J; Lee, N; Park, KM; Park, W | 1 |
| Camen, A; Ciobanu, GA; Georgescu, CC; Ionescu, M; Mercuț, R; Mogoantă, L; Munteanu, CM; Popescu, SM; Scrieciu, M; Staicu, IE; Vlad, D | 1 |
| Helm, A; Rao, NJ; Wang, JY; Yu, RQ; Zheng, LW | 1 |
| Abraham, AM; Aguirre, JI; Bhattacharyya, I; Castillo, EJ; Israel, R; Jiron, JM; Jorgensen, M; Kimmel, DB; Messer, JG; Reynolds, MC; Thomas, S; Van Poznak, C; Wanionok, N; Wnek, RD; Yarrow, JF | 1 |
| Arce, RM; Auersvald, CM; Awad, ME; Celis, E; Cutler, CW; Elashiry, M; Eldin M Elshikh, M; Elsalanty, ME; Elsayed, R; Gerber, J; Isales, C; Kurago, Z; Meghil, M; Sultan, H; Sun, C; Zeitoun, R | 1 |
| Adachi, N; Atsuta, I; Ayukawa, Y; Furuhashi, A; Imai, M; Koyano, K; Sanda, K; Yasunami, N | 1 |
| Daneshmand, M; Davoudi, A; Movahedian Attar, B; Razavi, SM | 1 |
| Cohen, G; Doppelt, O; Elimelech, R; Sabbah, N; Tamari, T; Zigdon-Giladi, H | 1 |
| Bai, X; He, L; Li, J; Liang, K; Su, Z; Tay, FR; Yuan, H; Zhang, M | 1 |
| Chefu, SG; Ignatova, VD; Kosach, GA; Kosach, SA; Kutukova, SI; Molokova, VA; Petrosyan, AL; Vlasov, TD; Yagmurov, OD; Yaremenko, AI; Zubareva, AA | 1 |
| Metzger, MC; Rothweiler, R; Schmelzeisen, R; Voss, PJ | 1 |
| de Alexandria Santos, DS; de Sales Lima, MV; E Silva de Carvalho, LFDC; Kitakawa, D; Magalhães, NC; Peralta, FDS; Scherma, ADP | 1 |
| Chang, HH; Cheng, SJ; Chiu, WY; Kok, SH; Lee, JJ; Lee, YC; Wang, JJ; Wei, LY | 1 |
| Bagramian, RA; Dakhil, SR; Darke, AK; Fisch, MJ; Floyd, JD; Gralow, J; Hansen, LK; Henry, NL; Hershman, DL; Lew, DL; Moinpour, C; Schubert, MM; Unger, JM; Van Poznak, CH; Wade, JL | 1 |
| Abraham, AM; Aguirre, JI; Alekseyenko, AV; Bhattacharyya, I; Castillo, EJ; Croft, S; Gohel, A; Gonzalez-Perez, GM; Israel, R; Jiron, JM; Kimmel, DB; Messer, JG; Novince, CM; Thomas, S; Yarrow, JF | 1 |
| Billias, C; Langer, M; Schorr, R; Ursu, S | 1 |
| Doi, K; Hashida, T; Hirabatake, M; Ikesue, H; Morimoto, M; Muroi, N; Takenobu, T; Yamamoto, S | 1 |
| Fujita, R; Hamano, H; Hiratsuka, S; Iwasaki, N; Kobayashi, H; Sato, D; Shimizu, T; Takahata, M | 1 |
| Cai, X; Finch, ER; Janke, LJ; Jenkins, DA; Karol, SE; Kim, J; Liu, Y; Payton, MA; Relling, MV | 1 |
| Halling, F; Lux, C; Otto, M; Schlittenbauer, T; Ziebart, T | 1 |
| Bergamaschi, CC; Ferreira, DC; Franquez, RT; Martins, LHI; Motta, RHL; Silva, MT | 1 |
| Funahara, M; Hayashida, S; Iwai, H; Kojima, Y; Murata, M; Otsuru, M; Saito, T; Sawada, S; Soutome, S; Umeda, M; Yanamoto, S | 1 |
| Hirasawa, N; Imatoh, T; Sai, K; Saito, Y; Segawa, K; Takeyama, M | 1 |
| Beth-Tasdogan, NH; Hussein, H; Mayer, B; Zolk, O | 1 |
| Leung, YY; Rao, NJ; Wang, JY; Yu, RQ; Zheng, LW | 1 |
| Estilo, CL; Huryn, JM; Liang, STY; Owosho, AA; Sax, AZ; Wu, K; Yom, SK | 1 |
| Casatti, CA; Cintra, LTA; de Almeida, JM; de Mello-Neto, JM; de Sá, DP; Ervolino, E; Garcia, VG; Issa, JPM; Nagata, MJH; Statkievicz, C; Theodoro, LH; Toro, LF | 1 |
| Benfica, JRD; Etges, A; Langie, R; Munaretto, JC; Pacheco, VN; Ponzoni, D; Puricelli, E | 1 |
| Jayaram, R; Thavarajah, M | 1 |
| Ebetino, FH; Evans, C; Hokugo, A; Kanayama, K; Lundy, MW; McKenna, CE; Morinaga, K; Nishimura, I; Okawa, H; Sadrerafi, K; Sasaki, H; Sun, S; Sun, Y; Wu, Q | 1 |
| Bafaloukos, D; Karagianni, A; Linardou, H; Michalakakou, K; Nicolatou-Galitis, O; Papadopoulou, E; Papassotiriou, I; Tarampikou, A; Tsixlakis, K; Vardas, E | 1 |
| Corradi, D; Govoni, P; Maestri, R; Mergoni, G; Passerini, P; Sala, R; Vescovi, P | 1 |
| Agarwala, S; Vijayvargiya, M | 1 |
| Dalla-Pozza, L; Little, DG; Munns, CF; Padhye, B | 1 |
| Cavo, M; Dimopoulos, MA; Drake, MT; Durie, BG; García-Sanz, R; Jurczyszyn, A; Leleu, X; Lentzsch, S; Merlini, G; Morgan, G; Munshi, N; Raje, N; Rajkumar, SV; Reiman, T; Roodman, GD; Sezer, O; Shimizu, K; Spencer, A; Terpos, E; Turesson, I | 1 |
| Shapiro, CL | 1 |
| Agrawal, R; Bell, R; Brown, JE; Cameron, D; Chakraborti, P; Coleman, RE; Collinson, M; Jyothirmayi, R; Liversedge, V; Marshall, HC; Murden, GA; Rathbone, EJ; Spensley, S; Yuille, F | 1 |
| Jung, HD; Jung, YS; Kim, DW; Park, HS | 1 |
| Catalfamo, L; Centofanti, A; Cutroneo, G; De Ponte, FS; Favaloro, A; Runci, M; Siniscalchi, EN | 1 |
| Gerngroß, C; Hahnefeld, L; Hohlweg-Majert, B; Jansen, H; Kehl, V; Koerdt, S; Otto, S; Pautke, C; Ristow, O; Schwaiger, M | 1 |
| Arellano, J; Bahl, A; Body, JJ; Gatta, F; Hauber, AB; Haynes, I; Hechmati, G; Mohamed, AF; Qian, Y; von Moos, R | 1 |
| Anderson, KC; Ghobrial, IM; Laubach, JP; Munshi, NC; Nemani, N; Patel, CG; Raje, NS; Richardson, PG; Santo, L; Schlossman, RL; Scullen, TA; Yee, AJ | 1 |
| Felsenberg, D; Gabbert, TI; Hoffmeister, B | 1 |
| Bedogni, A; Bettini, G; Bonacina, R; Campisi, G; Di Fede, O; Fusco, V; Guglielmini, P; Lo Re, G; Merigo, E; Paglino, C; Porta, C; Saia, G; Scoletta, M; Vescovi, P | 1 |
| Cho, YJ; Ha, YC; Kim, HJ; Kim, SY; Koo, KH; Lee, YK; Min, BW; Suh, KT; Won, YY; Yoon, TR | 1 |
| Bianchi, MG; Corradi, D; Govoni, P; Maestri, R; Mergoni, G; Merigo, E; Nammour, S; Passerini, P; Sala, R; Vescovi, P | 1 |
| Glotzbecker, B; Mawardi, H; Richardson, P; Woo, SB | 1 |
| Gomes Filho, JE; Kobayashi, J; Kobayashi, M; Matsuda, S; Ohba, S; Sano, K; Wayama, MT; Yoshida, H; Yoshimura, H | 1 |
| Soós, B; Szalma, J; Vajta, L | 1 |
| Kajizono, M; Kitamura, Y; Matsuoka, J; Sada, H; Sendo, T; Soga, Y; Sugiura, Y | 1 |
| Ghoshal, S; Henderson, W; Jang, SS; Kumar, S; Liu, Y; Niu, LN; Pashley, DH; Pramanik, C; Sood, P; Tay, FR; Yuan, H | 1 |
| Jiao, K; Kumar, S; Li, JY; Messer, R; Niu, LN; Pashley, DH; Pei, DD; Pramanik, C; Tay, FR; Yuan, H | 1 |
| Dalla-Pozza, L; Little, D; Munns, C; Padhye, B | 1 |
| Aras, MH; Bozdağ, Z; Çetiner, S; Demir, T; Erkılıç, S; Yanık, S | 1 |
| Alcántara-Montiel, JC; Arce-Cano, M; García-Campos, J; Lugo Reyes, SO; Sánchez-Sánchez, LM; Staines Boone, AT | 1 |
| Biguetti, CC; Fonseca, AC; Mada, EY; Matsumoto, MA; Neves, FT; Santos, AC; Saraiva, PP | 1 |
| Gallego, L; Junquera, L | 2 |
| Andreadis, C; Boukovinas, I; Koloutsos, G; Kyrgidis, A; Patrikidou, A; Teleioudis, Z; Triaridis, S; Vahtsevanos, K | 1 |
| Al-Nawas, B; Beck, J; Gamm, H; Grötz, KA; Thomas, C; Thüroff, JW; Wagner, W; Walter, C; Zinser, V | 1 |
| Cheng, JC; Wong, YK | 1 |
| Ascani, L; Bareggi, C; Brunelli, C; Campa, T; Cislaghi, E; Fagnoni, E; Maniezzo, M; Ripamonti, CI; Saibene, G | 1 |
| Bareggi, C; Bianchi, C; Borgonovo, K; Cobelli, S; Farina, G; Garassino, M; La Verde, N; Mantica, C; Mihali, D; Pedretti, D; Perrone, S; Rizzo, A; Sburlati, P | 1 |
| Bamia, C; Bamias, A; Christoulas, D; Dimopoulos, MA; Eleftherakis-Papaiakovou, E; Gika, D; Kastritis, E; Melakopoulos, I; Migkou, M; Roussou, M; Terpos, E | 1 |
| Bohle, GC; Carlson, DL; Estilo, CL; Farooki, A; Fornier, M; Halpern, JL; Huryn, JM; Lwin, PT; Riedel, ER; Schoder, H; Tunick, SJ; Van Poznak, CH; Wiliams, T; Zhou, Q | 1 |
| Anderson, KC; Lerman, MA; Lyng, GD; Sonis, ST; Watkins, BA | 1 |
| Kyrgidis, A; Teleioudis, Z; Vahtsevanos, K | 1 |
| Abati, S; Carmagnola, D; Celestino, S | 1 |
| Batuman, O; Berenson, JR; Boccia, RV; Duvivier, H; Flam, M; Moezi, MM; Nassir, Y; Swift, RA; Wong, SF; Woytowitz, D; Yellin, O | 1 |
| Berruti, A; Fusco, V; Ortega, C | 1 |
| Gallego, L; Junquera, L; Villarreal, P | 1 |
| Badros, A; Chaisuparat, R; Cullen, KJ; Meiller, TF; Scheper, MA | 1 |
| Bennett, CL; Boyd, I; Carson, K; Dimopoulos, M; Edwards, BJ; Farrugia, M; Gounder, M; Marx, R; McKoy, JM; Mehta, J; Migliorati, C; Obadina, E; Raisch, DW; Ruggiero, S; Singhal, S; Trifilio, S; West, D | 1 |
| Kyrgidis, A; Triaridis, S | 1 |
| Kogan, R; Lehrer, S; Montazem, A; Pessin-Minsley, M; Pfail, J; Ramanathan, L; Stock, RG | 1 |
| Andreadis, C; Kyrgidis, A | 1 |
| Frerich, B; Hemprich, A; Kluge, R; Sabri, O; Schulz, T; Steinhoff, K; Wilde, F; Winter, K | 1 |
| Abildgaard, N; Gregersen, H; Lund, T; Marker, P; Vangsted, A | 1 |
| Banys, M; Beck, V; Fehm, T; Hairass, M; Krimmel, M; Lipp, HP; Reinert, S; Solomayer, EF; Wallwiener, D | 1 |
| Chantrain, G; Decaestecker, C; Hupin, C; Javadian, R; Loeb, I; Magremanne, M; Saussez, S | 1 |
| Ayllon, J; Cros, C; Launay-Vacher, V; Medioni, J; Oudard, S; Spano, JP | 1 |
| Grötz, KA; Hafner, S; Otto, S | 1 |
| Grasko, JM; Herrmann, RP; Vasikaran, SD | 1 |
| Khan, AM; Sindwani, R | 1 |
| Aki, SZ; Cetiner, M; Cetiner, S; Gultekin, SE; Haznedar, R; Kahraman, SA; Kocakahyaoglu, B; Sucak, GT | 1 |
| Biasotto, M; Chiandussi, S; De Nardi, E; Di Lenarda, R; Dore, F; Tirelli, G | 1 |
| Kressley, A; Saif, MW; Smith, A | 1 |
| Elad, S; Hardan, I; Lazarovici, TS; Taicher, S; Yahalom, R; Yarom, N | 1 |
| Balasanian, E; Stanton, DC | 1 |
| Fakler, O; Gutwald, R; Liebehenschel, N; Sauerbier, S; Schmelzeisen, R; Wagner, K; Wongchuensoontorn, C | 1 |
| Oliver, RJ; Seehra, J; Sloan, P | 1 |
| Pierrot-Deseilligny Despujol, C; Pouchot, J | 1 |
| Fenner, M; Hinkmann, FM; Lell, MM; Neukam, FW; Nkenke, E; Stockmann, P; Vairaktaris, E | 1 |
| Baer, D; Han, MM; Hui, RL; Khoury, S; Liao, W; Liberty, D; Lo, JC; Martin, D; O'Ryan, FS | 1 |
| Eufinger, H; Hoefert, S; Schmitz, I; Tannapfel, A | 1 |
| Fernandez, SA; Huja, SS; Li, Y; Phillips, C | 1 |
| Allen, MR; Burr, DB | 1 |
| Badros, A; Cullen, KJ; Meiller, TF; Salama, AR; Scheper, MA; Warburton, G; Weikel, DS | 1 |
| Andreadis, CG; Antoniades, K; Boukovinas, I; Katodritou, E; Kitikidou, K; Koloutsos, GE; Kyrgidis, A; Paraskevopoulos, P; Teleioudis, Z; Triaridis, S; Vahtsevanos, K; Verrou, E; Zervas, K | 1 |
| Castellana, MA; Gasparini, G; Longo, R | 1 |
| Hata, K; Hiraga, T; Kobayashi, Y; Matsumoto-Nakano, M; Ueda, A; Wang, L; Yatani, H; Yoneda, T | 1 |
| Crawford, BS; Kraut, EH; McNulty, RM; Turowski, RC | 1 |
| Cankaya, M; Ersoz, S; Gunhan, O; Kadioglu Duman, M; Muci, E; Pampu, AA; Senel, FC | 1 |
| Danés, CF; Domingo, JP; Puigoriol, EB; Tuneu, NC | 1 |
| Divgi, C; Grewal, RK; Hudis, CA; Larson, S; Mak, AF; Modi, S; Morris, PG; Patil, S; Poznak, CV | 1 |
| Fossion, E; Huizing, MT; Van den Wyngaert, T; Vermorken, JB | 1 |
| Endo, Y; Funayama, H; Kawamura, H; Kumamoto, H; Kuroishi, T; Oizumi, T; Sasaki, K; Sugawara, S; Takahashi, H; Yamaguchi, K; Yamamoto, M; Yokoyama, M | 1 |
| Bernardeschi, P; D'Alessandro, M; Del Conte, A; Fiorentini, G; La Ferla, F; Montagnani, F; Turrisi, G | 1 |
| Adams, JS; Christensen, R; Chung, EM; Felsenfeld, AL; Garrett, N; Hokugo, A; Nishimura, I; Sayre, JW; Sung, EC | 1 |
| Akiyama, K; Chen, C; Chen, W; Kikuiri, T; Kim, I; Le, AD; Li, Y; Shi, S; Wang, S; Yamaza, T; Zhang, Q | 1 |
| Biasotto, M; Cavalli, F; Chiandussi, S; Contardo, L; Di Lenarda, R; Dore, F; Giacca, M; Moimas, S; Pozzato, G; Zacchigna, S; Zanconati, F | 1 |
| Oreadi, D; Papageorge, MB | 1 |
| Friedland, B; Treister, NS; Woo, SB | 1 |
| Bornstein, MM; Frei, M; Iizuka, T; Reichart, PA; Schaller, B; Weimann, R | 1 |
| Campisi, G; Colella, G; Fusco, V; Loidoris, A; Vescovi, P | 1 |
| Arduino, PG; Broccoletti, R; Dalmasso, P; Mozzati, M; Scoletta, M | 1 |
| Allen, MR; Burr, DB; Chu, TM; Kubek, DJ; Ruggiero, SL | 1 |
| Bi, Y; Cao, C; Ehirchiou, D; Gao, Y; Kikuiri, T; Le, A; Shi, S; Zhang, L | 1 |
| Bozas, G; Maraveyas, A; Ramasamy, V; Roy, A | 1 |
| Beninati, F; Ficarra, G | 1 |
| Lurie, R; Meer, S; Suleman, YF | 1 |
| McCauley, LK; Van Poznak, C; Yamashita, J | 1 |
| Azambuja, AA; Campos, MM; Cherubini, K; Maahs, MP; Salum, FG | 1 |
| Pozzi, S; Raje, N | 2 |
| Bauss, F; Drosse, I; Ehrenfeld, M; Opelz, C; Otto, S; Pautke, C; Schieker, M; Schwager, J; Westphal, I | 1 |
| Bauer, F; Ehrenfeld, M; Hafner, S; Hohlweg-Majert, B; Kolk, A; Kreutzer, K; Mast, G; Otto, S; Pautke, C; Steiner, T; Stürzenbaum, SR; Tischer, T; Weitz, J; Wolff, KD | 1 |
| Black, DM; Bucci-Rechtweg, C; Grbic, JT; Lyles, KW; McClung, M; Orwoll, E; Reid, DM; Su, G | 1 |
| Aapro, M; Costa, L; Saad, F | 1 |
| Mas, A; Mascaró, JM | 1 |
| Albu, S; Dinu, C | 1 |
| Acham, S; Jakse, N; Obermayer-Pietsch, B; Rugani, P; Truschnegg, A | 1 |
| Antonini, F; Azambuja, FG; Parente, EV; Pereira, CC | 1 |
| D'Atri, AM; Fenell, CE; Fernandez, SA; Hueni, S; Huja, SS; Mason, A; Mo, X | 1 |
| Liu, Y; Ning, J; Ravosa, MJ; Stack, MS | 1 |
| Koi, K; McCauley, LK; Yamashita, J; Yang, DY | 1 |
| Hollstein, S; Hölzle, F; Kriwalsky, MS; Kunkel, M; Maurer, P; Rashad, A; Sandulescu, T; Stricker, I | 1 |
| Brandi, ML; Cavalli, L; Cavalli, T; Falchetti, A; Marini, F; Masi, L; Tonelli, P | 1 |
| Díaz-Bobes, C; Gallego, L; Junquera, L; Pelaz, A | 1 |
| Arduino, PG; Battaglio, C; Berardi, D; Broccoletti, R; Chiecchio, A; Donadio, M; Gandolfo, S; Menegatti, E; Mozzati, M; Scoletta, M; Scully, C; Vandone, AM | 1 |
| Campisi, G; Colella, G; Favia, G; Fusco, V; Gabriele, M; Gaeta, GM; Manfredi, M; Mergoni, G; Merigo, E; Peluso, F; Solazzo, L; Vescovi, P | 1 |
| Ferlito, S; Liardo, C; Puzzo, S | 1 |
| Amann, K; Hyckel, P; Neukam, F; Nkenke, E; Ries, J; Schlegel, K; Stockmann, P; Wehrhan, F | 1 |
| Barrett-Lee, PJ; Bell, R; Brown, J; Burkinshaw, R; Cameron, D; Coleman, R; Davies, C; Dodwell, D; Gil, M; Grieve, RJ; Houston, SJ; Keane, M; Thorpe, H; Woodward, E | 1 |
| Burkley, B; Casanova, O; Ferreira, P; Gong, Y; Hou, W; Katz, J; Langaee, TY; Moreb, JS; Salmasinia, D | 1 |
| Friedlander, AH | 1 |
| Bouganim, N; Clemons, M; Finkelman, RD | 1 |
| Aapro, MS | 1 |
| Alloh Amichia, YC; Giumelli, B; Le Bars, P; Soueidan, A | 1 |
| Arbitrio, M; Baudi, F; Calimeri, T; Cannataro, M; Cucinotto, I; Di Martino, MT; Guzzi, PH; Leone, E; Piro, E; Prantera, T; Rossi, M; Tagliaferri, P; Tassone, P; Veltri, P | 1 |
| Body, JJ | 1 |
| Bargagli, G; Francini, E; Francini, F; Miano, ST; Pascucci, A; Petrioli, R; Ruggiero, G | 1 |
| Angeli, A; Berruti, A; Bertetto, O; Ciccone, G; Ciuffreda, L; Fusco, V; Galassi, C; Ortega, C | 1 |
| Baldwin, CM; D'Silva, NJ; Edwards, PC; Feinberg, SE; Krebsbach, PH; Kuo, S; Scheller, EL | 1 |
| Barbounis, V; Boziari, P; Karayianni, A; Kyrtsonis, MC; Migliorati, CA; Nicolatou-Galitis, O; Papadopoulou, E; Repousis, P; Sarri, T | 1 |
| Amann, K; Guentsch, A; Neukam, FW; Nkenke, E; Schlegel, KA; Stockmann, P; Wehrhan, F; Wehrhan, T | 1 |
| Antoniades, K; Arora, A; Kyrgidis, A | 1 |
| Kyrgidis, A; Tzellos, TG | 1 |
| Kami, M; Matayoshi, T; Takeuchi, K; Tanimoto, T; Yagasaki, F | 1 |
| Frustino, JL; Kossoff, EB; Ngamphaiboon, N; O'Connor, TL; Sullivan, MA | 1 |
| Morgan, GJ | 1 |
| Hewson, ID | 1 |
| Bartl, R | 1 |
| Barrett-Lee, PJ; Bell, R; Burkinshaw, R; Cameron, D; Coleman, RE; Davies, C; Dodwell, D; Gaunt, C; Gil, M; Gregory, W; Grieve, RJ; Hiley, V; Houston, SJ; Keane, M; Marshall, H; Peterson, J; Pugh, J; Rea, U; Ritchie, D | 1 |
| Andreadis, D; Epivatianos, A; Markopoulos, A; Mauroudis, S; Poulopoulos, A | 1 |
| Bonacina, R; Mariani, U; Villa, A; Villa, F | 1 |
| Colnot, C; Hu, D; Lieu, S; Miclau, T; Yu, YY | 1 |
| Azambuja, AA; Berti-Couto, SA; Cherubini, K; da Silva, VD; Figueiredo, MA; Salum, FG; Vasconcelos, AC | 1 |
| Arata, V; Gallesio, G; Mozzati, M | 1 |
| Basi, DL; Dudek, AZ; Gopalakrishnan, R; Huckabay, S; Hughes, PJ; Leach, JW; Lunos, S; Swenson, KK; Thumbigere-Math, V; Tu, L | 1 |
| Enomoto, Y; Fujimura, T; Fukuhara, H; Hirano, Y; Homma, Y; Igawa, Y; Ishikawa, A; Kume, H; Miyazaki, H; Nishimatsu, H; Suzuki, M | 1 |
| Uña, E | 1 |
| Li, Y; Ye, WC; Zhang, B | 1 |
| Carducci, MA; Paller, CJ; Philips, GK | 1 |
| De Smet, L; Degreef, I; Didden, K; Sciot, R; Vandenberghe, L | 1 |
| Bastit, L; El Kouri, C; Guérif, S; Ktiouet, M; Lebret, T; Lortholary, A; Mouysset, JL; Murraciole, X; Slimane, K | 1 |
| Marx, RE | 1 |
| Csermak, K; Tarassoff, P | 1 |
| Baldock, PA; Little, DG; Mcevoy, A; Peat, RA; Smith, EJ; Williams, PR | 1 |
| Carter, GD; Goss, AN | 1 |
| Greenberg, MS | 1 |
| Melo, MD; Obeid, G | 1 |
| Antonioli, E; Bosi, A; Ficarra, G; Vannucchi, AM | 1 |
| Gralow, J | 1 |
| Nelson, MV | 1 |
| Guarino, MJ; Hill, CE; Patel, K | 1 |
| Bagan, JV; Jimenez-Soriano, Y | 1 |
| Crowley, J; Durie, BG; Katz, M | 1 |
| Hande, K; Richardson, PG; Woo, SB | 1 |
| Duck, L; Maerevoet, M; Martin, C | 1 |
| Cox, M; Makani, S; Mander, C; Wragg, K | 1 |
| Hellie, CM; Olson, KB; Pienta, KJ | 1 |
| Bourgeois, SL; Goodell, GG; Sarathy, AP | 1 |
| Corradi, D; Manfredi, M; Meleti, M; Merigo, E; Vescovi, P | 1 |
| Broumand, V; Fortin, M; Marx, RE; Sawatari, Y | 1 |
| Fietkau, R; Gundlach, KK; Lenz, JH; Mueller, PC; Schmidt, W; Steiner-Krammer, B | 1 |
| Bagan, JV; Diaz, JM; Hernandez, S; Jimenez, Y; Murillo, J; Poveda, R; Sanchis, JM; Scully, C | 1 |
| Gibbs, SD; O'Grady, J; Prince, HM; Seymour, JF | 1 |
| Anagnostopoulos, A; Bamia, C; Bamias, A; Bozas, G; Dimopoulos, MA; Gika, D; Kastritis, E; Koutsoukou, V; Melakopoulos, I; Moulopoulos, LA; Papadimitriou, C; Terpos, E | 1 |
| Bess, AL; Hohneker, JA | 1 |
| Abi Najm, S; Carrel, JP; Lesclous, P; Lombardi, T; Lysitsa, S; Samson, J | 1 |
| Vastag, B | 1 |
| Aguirre, A; Campbell, JH; Margarone, JE; Markiewicz, MR | 1 |
| Etayo-Pérez, A; Garatea-Crelgo, J; Martino-Gorbea, R; Pastor-Zuazaga, D; Sebastián-López, C | 1 |
| Eufinger, H; Hoefert, S | 1 |
| Robb-Nicholson, C | 1 |
| Aglietta, M; Faggiuolo, R; Goia, F; Montemurro, F; Nanni, D; Ortega, C; Vormola, R | 1 |
| Ciccarelli, R; Fedele, S; Lo Muzio, L; Lo Russo, L; Mignogna, MD | 1 |
| Bishop, PA; Hay, KD | 1 |
| Alexander, RE | 1 |
| Soileau, KM | 1 |
| Farrar, SK | 1 |
| Englund, K; Hatch, C; Hussein, MA; Isada, C; Karam, MA; Licata, A; Reed, J; Richmond, M; Smith, J; Thakkar, SG; Tomford, JW | 1 |
| Dimitrakopoulos, I; Karakasis, D; Magopoulos, C | 1 |
| Elting, LS; Migliorati, CA; Siegel, MA | 1 |
| Anagnostopoulos, A; Bamia, C; Bamias, A; Dimopoulos, MA; Gika, D; Kastritis, E; Melakopoulos, I; Moulopoulos, LA; Terpos, E; Tsionos, K | 1 |
| Gregersen, H; Neumann, B | 1 |
| Biasotto, M; Cavalli, F; Chiandussi, S; Cova, MA; Di Lenarda, R; Dore, F | 1 |
| Acevedo, AC; Cavalcanti, MG; Figueiredo, PT; Guerra, EN; Leite, AF; Melo, NS; Paula, AP; Paula, LM | 1 |
| Weeda, LW | 1 |
| Kademani, D; Koka, S; Lacy, MQ; Rajkumar, SV | 1 |
| Braun, E; Iacono, VJ | 1 |
| Mahachoklertwattana, P | 1 |
| Baumann, A; Czerny, C; Eisenmenger, G; Ewers, R; Hoffmann, M; Moser, D; Pietschmann, P; Wutzl, A | 1 |
| Doyle-Lindrud, S | 1 |
| Aguiar Bujanda, D; Aguiar Morales, J; Bohn Sarmiento, U; Cabrera Suárez, MA | 1 |
| Baccarani, M; Brioli, A; Cangini, D; Catalano, L; Cavo, M; Ceccolini, M; Cellini, C; D'Arco, A; Di Raimondo, F; Offidani, M; Perrone, G; Ronconi, S; Tacchetti, P; Tosi, P; Tura, S; Zamagni, E | 1 |
| Adachi, JD; Beattie, K; Bobba, RS; Kumbhare, D; Parkinson, B | 1 |
| Battley, J; Jayathissa, S; Seneviratne, E | 1 |
| Calvo-Villas, JM; Carreter de Granda, E; Govantes Rodríguez, J; Sicilia Guillén, F; Tapia Torres, M | 1 |
| Alati, C; Allegra, A; Alonci, A; Cicciù, M; De Ponte, FS; Musolino, C; Nastro, E; Oteri, G; Quartarone, E | 1 |
| Aguiar Bujanda, D; Aguiar Morales, J; Bohn Sarmiento, U; Cabrera Suárez, MA; Quintero Pérez, S | 1 |
| Agurto P, J; Anguita C, T; Laissle C, G; Roa E, I | 1 |
| Bonaninil, M; Corcione, L; Corradi, D; D'Aleo, P; Ferrari, S; Guidotti, R; Manfredi, M; Meleti, M; Merigo, E; Poli, T; Ripasarti, A; Sesenna, E; Vescovi, P; Zanzucchi, E | 1 |
| Agazzi, A; D'Orto, O; Derada Troletti, G; Diego, R; Fontanella, W; Marzano, U; Pagani, D; Pignataro, L | 1 |
| Dannemann, C; Grätz, KW; Riener, MO; Zwahlen, RA | 1 |
| Araújo, SR; Cossolin, GS; Curi, MM; dos Santos, MO; Feher, O; Koga, DH; Zardetto, C | 1 |
| Anaissie, EJ; Boyette, J; Clarke, BM; Stack, BC; Suen, JY; Vural, E | 1 |
| de Visscher, JG; Schortinghuis, J; Spijkervet, KL; Witjes, MJ | 1 |
| Corso, A; Klersy, C; Lazzarino, M; Mangiacavalli, S; Pica, G; Varettoni, M; Zappasodi, P | 1 |
| Arpaci, F; Ataergin, S; Kanat, O; Komurcu, S; Kuzhan, O; Ozet, A; Ozturk, B; Ozturk, M | 1 |
| Compston, J | 1 |
| Lipton, A | 1 |
| Felicetti, L; Gissi, DB; Marchetti, C; Montebugnoli, L; Pelliccioni, GA; Pizzigallo, A | 1 |
| Jawad, AS; Shenker, NG | 1 |
| Aglietta, M; Faggiuolo, R; Gilardino, MO; Goia, F; Montemurro, F; Nanni, D; Ortega, C; Vormola, R | 1 |
| Briones, DL; Ferres, AJ; Herbozo, PJ; Torrealba, RL | 1 |
| Berman, AW; Brahim, JS; Denduluri, N; Goldman, ML; Guadagnini, JP; Kleiner, DE; Sausville, R; Swain, SM | 1 |
| Ashworth, D; Grew, N; Millar, B; Shetty, S; Srinivasan, D | 1 |
| Díaz Rubio, E; García Paredes, B; García Sáenz, JA; López Tarruella, S; Rodríguez Lajusticia, L; Villalobos, L | 1 |
| Engroff, SL; Kim, DD | 1 |
| Guthmiller, JM; Humbert, LA; Johnson, GK; Statz, TA | 1 |
| Bonneterre, J; Cortet, B; Facon, T; Maes, JM; Magro, L; Penel, G; Vieillard, MH | 1 |
| Bostan, F; Ozkaynak, C; Timurağaoğlu, A; Tuzuner, S; Undar, L | 1 |
| Borrás-Blasco, J; Casterá, E; Costa, S; Galan-Brotons, A; Giner-Marco, V; Rosique-Robles, D | 1 |
| Botelho, C; Cavaleiro, MV; Cortez, PP; Hussain, NS; Lobato, JV; Maurício, AC; Rodrigues, JM; Santos, JD; Xavier, L | 1 |
| Henderson, R; Ho, L; Quan, V | 1 |
| Casas, N; Delmas, PD; Eriksen, EF; Grbic, JT; Hua, Y; Landesberg, R; Leung, PC; Lin, SQ; Mesenbrink, P; Recknor, CP; Reid, IR | 1 |
| Cabezas Macián, A; Gutiérrez Pérez, JL; Infante Cossío, P; Palomino Nicas, J; Pérez Ceballos, JL | 1 |
| Brown, JJ; Ramalingam, L; Zacharin, MR | 1 |
| Abu-Id, MH; Acil, Y; Gottschalk, J; Kreusch, T; Russo, PA; Springer, I; Warnke, PH; Wiltfang, J | 1 |
| Agulló, FD; Estellés, RA; Jiménez, JA; López, CC | 1 |
| Bedogni, A; Bedogni, G; Blandamura, S; Chiarini, L; Ferrari, F; Ferretti, M; Ferronato, G; Lo Muzio, L; Lo Russo, L; Lokmic, Z; Ninfo, V; Nocini, PF; Palumbo, C; Pietrogrande, F; Procopio, O; Ragazzo, M; Saia, G; Tregnaghi, A | 1 |
| Caruso, PA; Dodson, TB; Raje, NS; Rosenberg, AE | 1 |
| Dodson, TB; Wessel, JH; Zavras, AI | 1 |
| Altundag, K; Bulut, N; Sari, E | 1 |
| Bagan, JV; Gómez, D; Jiménez, Y; Poveda, R; Scully, C; Sirera, R | 1 |
| Márton, I; Redl, P; Udvardy, E | 1 |
| Moore, S; Reilly, MM | 1 |
| De Zorzi, Pde M; Lovat, CP; Reiriz, AB | 1 |
| Gueiros, LA; Leão, JC; Lopes, MA | 1 |
22 review(s) available for zoledronic acid and Osteonecrosis
| Article | Year |
|---|---|
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Humans; Male; Osteonecrosis; Prostatic Neoplasms; Zoledronic Acid | 2022 |
Frequency of osteonecrosis in bisphosphonate users submitted to dental procedures: A systematic review.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Humans; Osteonecrosis; Osteoporosis; Zoledronic Acid | 2023 |
Interventions for managing medication-related osteonecrosis of the jaw.
Topics: Angiogenesis Inhibitors; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Denosumab; Dental Care; Diphosphonates; Female; Humans; Hyperbaric Oxygenation; Imidazoles; Intercellular Signaling Peptides and Proteins; Jaw Diseases; Male; Oral Health; Osteonecrosis; Postoperative Complications; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Time Factors; Tooth Extraction; Zoledronic Acid | 2017 |
Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Diphosphonates; Female; Humans; Imidazoles; Indoles; Italy; Jaw; Kidney Neoplasms; Male; Middle Aged; Osteonecrosis; Pyrroles; Retrospective Studies; Sunitinib; Zoledronic Acid | 2015 |
Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw.
Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Drug Approval; Female; Humans; Imidazoles; Incidence; Infusions, Intravenous; Jaw; Male; Osteonecrosis; Pamidronate; Precipitating Factors; Tooth Extraction; United States; United States Food and Drug Administration; Zoledronic Acid | 2008 |
Bisphosphonate-related osteonecrosis of the jaws: an update on clinical, pathological and management aspects.
Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Mandible; Osteonecrosis; Pamidronate; Retrospective Studies; Zoledronic Acid | 2007 |
Bisphosphonate-induced osteonecrosis of the jaws: review, clinical implications and case report.
Topics: Aged; Bone Density Conservation Agents; Contraindications; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Osteonecrosis; Zoledronic Acid | 2007 |
Updates on osteonecrosis of the jaw.
Topics: Angiogenesis Inhibitors; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw; Neoplasms; Osteonecrosis; Risk Factors; Zoledronic Acid | 2010 |
Osteonecrosis of the jaw and the role of macrophages.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Denosumab; Diphosphonates; Etidronic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibandronic Acid; Imidazoles; Indoles; Jaw Diseases; Macrophages; Magnetic Resonance Imaging; Mevalonic Acid; Monocytes; Mouth Mucosa; Osteoclasts; Osteomyelitis; Osteonecrosis; Positron-Emission Tomography; Pyrroles; Radiography, Panoramic; RANK Ligand; Risedronic Acid; Risk Factors; Signal Transduction; Sunitinib; Tomography, X-Ray Computed; Vitamin D; Zoledronic Acid | 2011 |
The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.
Topics: Acute-Phase Reaction; Bone Diseases; Diphosphonates; Endothelial Cells; Humans; Imidazoles; Multiple Myeloma; Osteoclasts; Osteocytes; Osteonecrosis; Pamidronate; Practice Guidelines as Topic; Zoledronic Acid | 2011 |
New developments for treatment and prevention of bone metastases.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Jaw; Male; Neoplasm Recurrence, Local; Osteonecrosis; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid | 2011 |
[Bisphosphonate related osteonecrosis of the jaws: a case report and review of the literature].
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw; Osteonecrosis; Zoledronic Acid | 2012 |
Management of bone metastases in refractory prostate cancer--role of denosumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Denosumab; Diphosphonates; Disease-Free Survival; Humans; Hypocalcemia; Imidazoles; Male; Orchiectomy; Osteonecrosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; RANK Ligand; Zoledronic Acid | 2012 |
Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Osteonecrosis; Pamidronate; Quality of Life; Randomized Controlled Trials as Topic; United States; Women's Health; Zoledronic Acid | 2005 |
Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid.
Topics: Adenocarcinoma; Androgen Antagonists; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Prostatic Neoplasms; Treatment Failure; Zoledronic Acid | 2005 |
Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Neoplasms; Osteonecrosis; Tooth Extraction; Zoledronic Acid | 2006 |
Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Dental Care for Chronically Ill; Diphosphonates; Humans; Imidazoles; Jaw; Mandibular Diseases; Multiple Myeloma; Osteonecrosis; Pamidronate; Practice Guidelines as Topic; Time Factors; Zoledronic Acid | 2006 |
Bisphosphonate-associated osteonecrosis of the jaws. Report of a case and literature review.
Topics: Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Male; Maxillary Diseases; Osteonecrosis; Zoledronic Acid | 2006 |
Implications of androgen-deprivation therapy in patients with prostate cancer: A case study.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Combined Modality Therapy; Diphosphonates; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Jaw Diseases; Leuprolide; Male; Orchiectomy; Osteonecrosis; Osteoporosis; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, Conformal; Risk Factors; Tomography, X-Ray Computed; Zoledronic Acid | 2006 |
Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Osteonecrosis; Osteoporosis; Risedronic Acid; Zoledronic Acid | 2006 |
The safety of zoledronic acid.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Creatinine; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Kidney; Osteonecrosis; Product Surveillance, Postmarketing; Zoledronic Acid | 2007 |
[Osteonecrosis of the jaw developing during bisphosphonate treatment].
Topics: Alendronate; Anti-Infective Agents; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Mandible; Mandibular Diseases; Oral Hygiene; Oral Surgical Procedures; Osteonecrosis; Patient Care Team; Referral and Consultation; Zoledronic Acid | 2008 |
17 trial(s) available for zoledronic acid and Osteonecrosis
| Article | Year |
|---|---|
Nitrogen-containing bisphosphonate therapy-Part II: Assessment of alveolar bone tissue inflammatory response in rats-A blind randomized controlled trial.
Topics: Alveolar Process; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Remodeling; Diphosphonates; Disease Models, Animal; Inflammation; Male; Nitrogen; Osteonecrosis; Rats; Rats, Wistar; Tomography, X-Ray Computed; Zoledronic Acid | 2018 |
Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Middle Aged; Oral Health; Osteonecrosis; Quality of Life; Zoledronic Acid | 2013 |
Does Zoledronate Prevent Femoral Head Collapse from Osteonecrosis? A Prospective, Randomized, Open-Label, Multicenter Study.
Topics: Adolescent; Adult; Aged; Arthroplasty, Replacement, Hip; Bone Density Conservation Agents; Diphosphonates; Female; Femur Head; Humans; Imidazoles; Male; Middle Aged; Osteonecrosis; Prospective Studies; Treatment Outcome; Zoledronic Acid | 2015 |
Incidence and outcome of osteonecrosis in children and adolescents after intensive therapy for acute lymphoblastic leukemia (ALL).
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonates; Female; Follow-Up Studies; Glucocorticoids; Humans; Imidazoles; Incidence; Magnetic Resonance Imaging; Male; Neoplasm, Residual; Osteonecrosis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Zoledronic Acid | 2016 |
Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Female; Humans; Imidazoles; Lumbar Vertebrae; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Osteonecrosis; Radiography; Time Factors; X-Rays; Zoledronic Acid | 2008 |
Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study.
Topics: Aged; Bone Density Conservation Agents; Bone Marrow; Contrast Media; Diphosphonates; Female; Follow-Up Studies; Gadolinium; Humans; Imidazoles; Jaw Diseases; Magnetic Resonance Imaging; Male; Mandibular Diseases; Maxillary Diseases; Organometallic Compounds; Osteolysis; Osteonecrosis; Pamidronate; Radiography, Panoramic; Tomography, X-Ray Computed; Zoledronic Acid | 2010 |
Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Jaw Diseases; Middle Aged; Osteonecrosis; Radionuclide Imaging; Radiopharmaceuticals; Technetium Tc 99m Medronate; Zoledronic Acid | 2010 |
The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program.
Topics: Biomarkers; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Collagen Type I; Databases as Topic; Diphosphonates; Female; Follow-Up Studies; Forecasting; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Osteonecrosis; Osteoporosis, Postmenopausal; Peptides; Placebos; Prevalence; Risk Factors; United States; Zoledronic Acid | 2010 |
Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.
Topics: Adult; Aged; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Imidazoles; Incidence; Jaw Diseases; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Osteonecrosis; Treatment Outcome; Zoledronic Acid | 2011 |
Safety and efficacy of zoledronic acid in multiple myeloma.
Topics: Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Imidazoles; Incidence; Male; Multiple Myeloma; Osteonecrosis; Prognosis; Risk Assessment; Safety Management; Severity of Illness Index; Survival Analysis; Thromboembolism; Zoledronic Acid | 2011 |
Safety and efficacy of zoledronic acid in multiple myeloma.
Topics: Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Multiple Myeloma; Osteonecrosis; Prognosis; Risk Assessment; Safety Management; Survival Analysis; Thromboembolism; Treatment Outcome; Zoledronic Acid | 2011 |
Breast-cancer adjuvant therapy with zoledronic acid.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Osteonecrosis; Zoledronic Acid | 2011 |
Tooth extraction in patients on zoledronic acid therapy.
Topics: Case-Control Studies; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Radiography, Panoramic; Tomography, X-Ray Computed; Tooth Extraction; Zoledronic Acid | 2012 |
Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Risk; Time Factors; Zoledronic Acid | 2006 |
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Dexamethasone; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Retrospective Studies; Thalidomide; Zoledronic Acid | 2006 |
Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Analysis of Variance; Anti-Bacterial Agents; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Linear Models; Male; Metronidazole; Middle Aged; Osteonecrosis; Pamidronate; Prospective Studies; Zoledronic Acid | 2007 |
Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Epidemiologic Methods; Female; Hip Fractures; Humans; Imidazoles; Jaw Diseases; Middle Aged; Osteitis; Osteomyelitis; Osteonecrosis; Osteoporosis, Postmenopausal; Periapical Abscess; Zoledronic Acid | 2008 |
249 other study(ies) available for zoledronic acid and Osteonecrosis
| Article | Year |
|---|---|
Effects of Soft Tissue Closure on Medication-Related Osteonecrosis of the Jaw in a Rabbit Model with Tooth Extraction: A Pilot Study.
Topics: Animals; Bicuspid; Bone Density; Female; Jaw Diseases; Mandible; Models, Animal; Osteonecrosis; Pilot Projects; Rabbits; Tooth; Tooth Extraction; Tooth Socket; Zoledronic Acid | 2021 |
Significance of bisphosphonates on angiogenesis in vivo and their effect under geranyl-geraniol addition - could it alter the treatment of bisphosphonate-associated necrosis of the jaw?
Topics: Acyclic Monoterpenes; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Mice; Osteonecrosis; Zoledronic Acid | 2023 |
Long-Term Ligature-Induced Periodontitis Exacerbates Development of Bisphosphonate-Related Osteonecrosis of the Jaw in Mice.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Mice; Osteonecrosis; Periodontitis; Tooth Extraction; Zoledronic Acid | 2022 |
Absence of medication-related jaw osteonecrosis after treatment with strontium ranelate in ovariectomized rats.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Female; Osteonecrosis; Rats; Thiophenes; Tooth Extraction; Zoledronic Acid | 2022 |
Prognosis of metastatic bone cancer and myeloma patients and long-term risk of medication-related osteonecrosis of the jaw (MRONJ): some critical points.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Neoplasms; Humans; Incidence; Multiple Myeloma; Osteonecrosis; Prognosis; Retrospective Studies; Zoledronic Acid | 2022 |
Medication-Related Osteonecrosis of the Jaws in the Pediatric Population.
Topics: Adolescent; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Child; Child, Preschool; Denosumab; Diphosphonates; Female; Humans; Immunosuppressive Agents; Infant; Infant, Newborn; Jaw; Male; Osteonecrosis; Pamidronate; Retrospective Studies; Zoledronic Acid | 2022 |
Atorvastatin reduces zoledronic acid-induced osteonecrosis of the jaws of rats.
Topics: Animals; Atorvastatin; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Jaw; Osteonecrosis; Rats; Zoledronic Acid | 2022 |
Atorvastatin reduces zoledronic acid-induced osteonecrosis of the jaws of rats.
Topics: Animals; Atorvastatin; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Jaw; Osteonecrosis; Rats; Zoledronic Acid | 2022 |
Augmentation of IFN-γ by bone marrow derived immune cells in the presence of severe suppression of IFN-γ in gingivae induced by zoledronic acid and denosumab in Hu-BLT mice model of ONJ.
Topics: Animals; Bone Marrow; Denosumab; Diphosphonates; Gingiva; Humans; Interferon-gamma; Mice; Osteonecrosis; Zoledronic Acid | 2023 |
Exosomes Derived from Adipose Tissue-Derived Mesenchymal Stromal Cells Prevent Medication-Related Osteonecrosis of the Jaw through IL-1RA.
Topics: Animals; Collagen; Exosomes; Humans; Interleukin 1 Receptor Antagonist Protein; Mesenchymal Stem Cells; Mice; Osteonecrosis; X-Ray Microtomography; Zoledronic Acid | 2023 |
[Risk Factors of Antiresorptive Agent-Related Osteonecrosis of the Jaw in Prostate Cancer Patients with Bone Metastases].
Topics: Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Humans; Male; Osteonecrosis; Prostatic Neoplasms; Risk Factors; Zoledronic Acid | 2023 |
Menaquinone-4 prevents medication-related osteonecrosis of the jaw through the SIRT1 signaling-mediated inhibition of cellular metabolic stresses-induced osteoblast apoptosis.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Diphosphonates; Mice; Osteoblasts; Osteonecrosis; Signal Transduction; Sirtuin 1; Stress, Physiological; Zoledronic Acid | 2023 |
Preventive effect of teriparatide on medication-related osteonecrosis of the jaw in rats.
Topics: Animals; Female; Osteonecrosis; Rats; Rats, Sprague-Dawley; Teriparatide; X-Ray Microtomography; Zoledronic Acid | 2023 |
Correlations between Immune Response and Etiopathogenic Factors of Medication-Related Osteonecrosis of the Jaw in Cancer Patients Treated with Zoledronic Acid.
Topics: Humans; Mandible; Neoplasms; Osteonecrosis; Quality of Life; Retrospective Studies; Zoledronic Acid | 2023 |
Effect of Periapical Diseases in Development of MRONJ in Immunocompromised Mouse Model.
Topics: Alveolar Bone Loss; Animals; Bone Density; Bone Density Conservation Agents; Dexamethasone; Disease Models, Animal; Female; Mandible; Mice; Mice, Inbred C57BL; Molar; Osteonecrosis; Ovariectomy; Periapical Diseases; X-Ray Microtomography; Zoledronic Acid | 2019 |
Anti-vascular endothelial growth factor antibody monotherapy causes destructive advanced periodontitis in rice rats (Oryzomys palustris).
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Male; Osteonecrosis; Periodontitis; Rats; Sigmodontinae; X-Ray Microtomography; Zoledronic Acid | 2020 |
Role of dendritic cell-mediated immune response in oral homeostasis: A new mechanism of osteonecrosis of the jaw.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Cell Differentiation; Dendritic Cells; Homeostasis; Imidazoles; Jaw Diseases; Osteoclasts; Osteonecrosis; Tooth Extraction; Wound Healing; Zoledronic Acid | 2020 |
Preventive effect of fluvastatin on the development of medication-related osteonecrosis of the jaw.
Topics: Angiogenesis Inhibitors; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone and Bones; Bone Density Conservation Agents; Denosumab; Diphosphonates; Disease Models, Animal; Female; Fluvastatin; Osteonecrosis; Rats; Rats, Wistar; Tooth Extraction; Zoledronic Acid | 2020 |
Protective effects of resveratrol against osteonecrosis at the extraction site in bisphosphonate-treated rats.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Male; Osteonecrosis; Rats; Rats, Wistar; Resveratrol; Tooth Extraction; Zoledronic Acid | 2020 |
Endothelial progenitors increase vascularization and improve fibroblasts function that prevent medication-related osteonecrosis of the jaw.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Fibroblasts; Osteonecrosis; Rats; Rats, Inbred Lew; Zoledronic Acid | 2020 |
Borate bioactive glass prevents zoledronate-induced osteonecrosis of the jaw by restoring osteogenesis and angiogenesis.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Borates; Diphosphonates; Osteogenesis; Osteonecrosis; Rats; Zoledronic Acid | 2020 |
Disorders of microcirculation in the mechanism of bisphosphonate osteonecrosis: preliminary study in rats.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Imidazoles; Microcirculation; Osteonecrosis; Rats; Tooth Extraction; Zoledronic Acid | 2020 |
Medication-related osteonecrosis of the mandible: an unusual presentation and treatment.
Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cone-Beam Computed Tomography; Female; Humans; Mandible; Osteonecrosis; Zoledronic Acid | 2021 |
An Approach for the Prevention, Diagnosis, and Treatment of Jaw Osteonecrosis: Report of a Case Associated with Zoledronic Acid.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Middle Aged; Neoplasms; Osteonecrosis; Zoledronic Acid | 2020 |
Prognosis of medication-related osteonecrosis of the jaws in cancer patients using antiresorptive agent zoledronic acid.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Jaw; Male; Osteonecrosis; Prognosis; Retrospective Studies; Zoledronic Acid | 2021 |
Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Osteonecrosis; Prospective Studies; Zoledronic Acid | 2021 |
Preventing or controlling periodontitis reduces the occurrence of osteonecrosis of the jaw (ONJ) in rice rats (Oryzomys palustris).
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Humans; Jaw; Male; Osteonecrosis; Periodontitis; Rats; Sigmodontinae; Zoledronic Acid | 2021 |
Safety and efficacy of bone-modifying agents among multiple myeloma patients: A retrospective cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Hypocalcemia; Middle Aged; Multiple Myeloma; Osteonecrosis; Retrospective Studies; Young Adult; Zoledronic Acid | 2022 |
Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.
Topics: Aged; Angiogenesis Inhibitors; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Female; Humans; Incidence; Jaw; Male; Middle Aged; Osteonecrosis; Retrospective Studies; Risk Factors; Tooth Extraction; Zoledronic Acid | 2021 |
Differential effects of anti-RANKL monoclonal antibody and zoledronic acid on necrotic bone in a murine model of Staphylococcus aureus-induced osteomyelitis.
Topics: Animals; Antibodies, Monoclonal; Bone Density Conservation Agents; Disease Models, Animal; Ligands; Mice; Osteoclasts; Osteolysis; Osteomyelitis; Osteonecrosis; RANK Ligand; Staphylococcal Infections; Staphylococcus aureus; X-Ray Microtomography; Zoledronic Acid | 2022 |
Effects of zoledronic acid on osteonecrosis and acute lymphoblastic leukemia treatment efficacy in preclinical models.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Diphosphonates; Imidazoles; Mice; Osteonecrosis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome; X-Ray Microtomography; Zoledronic Acid | 2021 |
Geranyl-geraniol addition affects potency of bisphosphonates-a comparison in vitro promising a therapeutic approach for bisphosphonate-associated osteonecrosis of the jaw and oral wound healing.
Topics: Acyclic Monoterpenes; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Clodronic Acid; Diphosphonates; Endothelial Cells; Humans; Ibandronic Acid; Jaw Diseases; Mouth Diseases; Osteonecrosis; Wound Healing; Zoledronic Acid | 2022 |
Relationship between tooth extraction and development of medication-related osteonecrosis of the jaw in cancer patients.
Topics: Aged; Bone Density Conservation Agents; Denosumab; Female; Humans; Jaw; Male; Middle Aged; Multivariate Analysis; Neoplasms; Osteonecrosis; Propensity Score; Retrospective Studies; Risk Assessment; Risk Factors; Tooth Extraction; Zoledronic Acid | 2021 |
Influence of Japanese Regulatory Action on Denosumab-Related Hypocalcemia Using Japanese Adverse Drug Event Report Database.
Topics: Adverse Drug Reaction Reporting Systems; Algorithms; Asian People; Bone Density Conservation Agents; Databases, Factual; Denosumab; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Japan; Jaw Diseases; Logistic Models; Odds Ratio; Osteonecrosis; Zoledronic Acid | 2017 |
Role of Periapical Diseases in Medication-Related Osteonecrosis of the Jaws.
Topics: Alveolar Bone Loss; Animals; Bone Density; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Humans; Imidazoles; Jaw; Mandible; Mice; Molar; Necrosis; Osteocytes; Osteonecrosis; Periapical Diseases; Tomography, X-Ray Computed; Zoledronic Acid | 2017 |
Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
Topics: Adult; Aged; Angiogenesis Inhibitors; Bevacizumab; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Incidence; Indoles; Ipilimumab; Jaw Diseases; Male; Middle Aged; Neoplasms; Osteonecrosis; Pamidronate; Pyrroles; Retrospective Studies; Sunitinib; Zoledronic Acid | 2018 |
Photomodulation multiple sessions as a promising preventive therapy for medication-related osteonecrosis of the jaws after tooth extraction in rats.
Topics: Animals; Immunohistochemistry; Jaw; Low-Level Light Therapy; Osteonecrosis; Rats; Tooth Extraction; Zoledronic Acid | 2018 |
Uncommon presentation of medication-related osteonecrosis of the mandible in a patient with metastatic prostate cancer.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Bone Density Conservation Agents; Free Radical Scavengers; Humans; Male; Mandible; Osteonecrosis; Pentoxifylline; Prostatic Neoplasms; Vitamin E; Zoledronic Acid | 2019 |
Rescue bisphosphonate treatment of alveolar bone improves extraction socket healing and reduces osteonecrosis in zoledronate-treated mice.
Topics: Administration, Intravenous; Animals; Bone Density Conservation Agents; Diphosphonates; Female; Mice; Mice, Inbred C57BL; Osteonecrosis; Wound Healing; Zoledronic Acid | 2019 |
The use of crevicular fluid to assess markers of inflammation and angiogenesis, IL-17 and VEGF, in patients with solid tumors receiving zoledronic acid and/or bevacizumab.
Topics: Aged; Aged, 80 and over; Bevacizumab; Biomarkers; Drug Therapy, Combination; Female; Gingival Crevicular Fluid; Humans; Inflammation; Interleukin-17; Male; Middle Aged; Neoplasms; Neovascularization, Pathologic; Osteonecrosis; Periodontal Diseases; Periodontal Pocket; Predictive Value of Tests; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2020 |
Effects of zoledronic acid and dexamethasone on early phases of socket healing after tooth extraction in rats: A preliminary macroscopic and microscopic quantitative study.
Topics: Animals; Bone Density Conservation Agents; Dexamethasone; Diphosphonates; Humans; Male; Osteonecrosis; Rats; Rats, Sprague-Dawley; Tooth Extraction; Tooth Socket; Zoledronic Acid | 2019 |
Bisphosphonate combination therapy for non-femoral avascular necrosis.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Osteonecrosis; Prospective Studies; Young Adult; Zoledronic Acid | 2019 |
Use of zoledronic acid for treatment of chemotherapy related osteonecrosis in children and adolescents: a retrospective analysis.
Topics: Adolescent; Arthralgia; Arthroplasty; Bone Density; Bone Density Conservation Agents; Child; Diphosphonates; Female; Humans; Imidazoles; Lymphoma; Male; Osteonecrosis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiography; Retrospective Studies; Time Factors; Zoledronic Acid | 2013 |
International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.
Topics: Administration, Intravenous; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Combined Modality Therapy; Diphosphonates; Drug Therapy, Combination; Fractures, Bone; Humans; Imidazoles; International Cooperation; Magnetic Resonance Imaging; Medical Oncology; Multiple Myeloma; Osteonecrosis; Outcome Assessment, Health Care; Pamidronate; Positron-Emission Tomography; Practice Guidelines as Topic; Radiotherapy; Tomography, X-Ray Computed; Zoledronic Acid | 2013 |
Bisphosphonate-related osteonecrosis of jaw in the adjuvant breast cancer setting: risks and perspective.
Topics: Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Zoledronic Acid | 2013 |
Osteonecrosis of the jaw related to everolimus: a case report.
Topics: Angiogenesis Inhibitors; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Everolimus; Follow-Up Studies; Humans; Imidazoles; Male; Mandibular Diseases; Middle Aged; Osteonecrosis; Sirolimus; Thyroid Neoplasms; Thyroidectomy; Zoledronic Acid | 2013 |
Sarcoglycans and integrins in bisphosphonate treatment: immunohistochemical and scanning electron microscopy study.
Topics: Bone Neoplasms; Bone Resorption; Calcification, Physiologic; Cell Adhesion; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Humans; Imidazoles; Immunohistochemistry; Integrins; Jaw; Microscopy, Electron, Scanning; Mouth Mucosa; Osteonecrosis; Pamidronate; Sarcoglycans; Zoledronic Acid | 2013 |
Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Carcinoma; Denosumab; Diphosphonates; Female; Femur; Frontal Bone; Humans; Image Processing, Computer-Assisted; Imidazoles; Jaw Diseases; Mandible; Maxilla; Middle Aged; Osteonecrosis; Radionuclide Imaging; RANK Ligand; Retrospective Studies; Zoledronic Acid | 2014 |
Patients' preferences for bone metastases treatments in France, Germany and the United Kingdom.
Topics: Adult; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Choice Behavior; Denosumab; Diphosphonates; Female; France; Germany; Humans; Imidazoles; Kidney Diseases; Male; Middle Aged; Osteonecrosis; Pain; Patient Participation; Patient Preference; RANK Ligand; Treatment Outcome; United Kingdom; Zoledronic Acid | 2015 |
Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Collagen Type I; Cytokines; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Osteonecrosis; Pamidronate; Peptides; Prognosis; Zoledronic Acid | 2014 |
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Germany; Hematologic Neoplasms; Humans; Ibandronic Acid; Imidazoles; Jaw Diseases; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multiple Myeloma; Neoplasms; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Registries; Risk Factors; Sex Factors; Time Factors; Zoledronic Acid | 2015 |
The effect of laser therapy on the expression of osteocalcin and osteopontin after tooth extraction in rats treated with zoledronate and dexamethasone.
Topics: Animals; Anti-Inflammatory Agents; Bone Density Conservation Agents; Combined Modality Therapy; Dexamethasone; Diphosphonates; Imidazoles; Low-Level Light Therapy; Male; Osteocalcin; Osteonecrosis; Osteopontin; Rats; Rats, Sprague-Dawley; Tooth Extraction; Tooth Socket; Wound Healing; Zoledronic Acid | 2016 |
Hematopoietic Cell Transplantation in Patients with Medication-Related Osteonecrosis of the Jaws.
Topics: Aged; Antineoplastic Agents; Diphosphonates; Female; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Jaw; Male; Middle Aged; Osteonecrosis; Pamidronate; Retrospective Studies; Staphylococcus aureus; Transplantation Conditioning; Zoledronic Acid | 2016 |
Diminished Progression of Periapical Lesions with Zoledronic Acid in Ovariectomized Rats.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Disease Progression; Female; Imidazoles; Immunohistochemistry; Osteonecrosis; Ovariectomy; Periapical Periodontitis; Rats, Wistar; X-Ray Microtomography; Zoledronic Acid | 2015 |
[Sunitinib and zoledronic acid induced osteonecrosis of the jaw].
Topics: Adult; Antineoplastic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Indoles; Mandible; Oral Surgical Procedures; Osteonecrosis; Pyrroles; Sunitinib; Treatment Outcome; Zoledronic Acid | 2015 |
Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.
Topics: Aged; Anemia; Bone Density Conservation Agents; Bone Diseases; Denosumab; Dental Care; Diabetes Complications; Diphosphonates; Female; Humans; Imidazoles; Incidence; Jaw; Logistic Models; Male; Middle Aged; Neoplasms; Odds Ratio; Osteonecrosis; Retrospective Studies; Risk Factors; Zoledronic Acid | 2015 |
A mechanistic study of the interaction of water-soluble borate glass with apatite-bound heterocyclic nitrogen-containing bisphosphonates.
Topics: Apatites; Bone and Bones; Borates; Calcification, Physiologic; Cations; Computer Simulation; Diphosphonates; Durapatite; Glass; Humans; Imidazoles; Ions; Jaw; Magnesium; Magnetic Resonance Spectroscopy; Nitrogen; Osteonecrosis; Protons; Solubility; Water; X-Ray Diffraction; Zoledronic Acid | 2016 |
Revival of nitrogen-containing bisphosphonate-induced inhibition of osteoclastogenesis and osteoclast function by water-soluble microfibrous borate glass.
Topics: Animals; Apoptosis; Bone Resorption; Borates; Cell Differentiation; Diphosphonates; Glass; Imidazoles; Macrophages; Mice; Microscopy, Electron, Transmission; Nitrogen; Osteoclasts; Osteonecrosis; Oxidative Stress; RANK Ligand; RAW 264.7 Cells; Reactive Oxygen Species; Risedronic Acid; Water; Zoledronic Acid | 2016 |
Histopathological features of bisphosphonates related osteonecrosis of the jaw in rats with and without vitamin d supplementation.
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Dexamethasone; Diphosphonates; Disease Models, Animal; Imidazoles; Jaw; Male; Maxilla; Orthognathic Surgical Procedures; Osteoblasts; Osteoclasts; Osteonecrosis; Rats; Rats, Wistar; Tooth Extraction; Vitamin D; Zoledronic Acid | 2016 |
Zoledronate as effective treatment for minimal trauma fractures in a child with STAT3 deficiency and osteonecrosis of the hip.
Topics: Bone Density Conservation Agents; Child; Diphosphonates; Fractures, Bone; Hip; Humans; Imidazoles; Male; Osteonecrosis; STAT3 Transcription Factor; Zoledronic Acid | 2016 |
Effects of green tea and bisphosphonate association on dental socket repair of rats.
Topics: Animals; Core Binding Factor Alpha 1 Subunit; Diphosphonates; Drug Combinations; Imidazoles; Immunohistochemistry; Leukocytes; Male; Maxilla; Osteonecrosis; Osteoprotegerin; Plant Extracts; Rats; Rats, Wistar; Tartrate-Resistant Acid Phosphatase; Tea; Tooth Socket; Wound Healing; Zoledronic Acid | 2017 |
Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant?
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Mandible; Middle Aged; Osteonecrosis; Zoledronic Acid | 2008 |
Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients.
Topics: Adult; Aged; Bone Density Conservation Agents; Breast Neoplasms; Case-Control Studies; Chi-Square Distribution; Dental Care for Chronically Ill; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Logistic Models; Middle Aged; Osteonecrosis; Retrospective Studies; Risk Factors; Zoledronic Acid | 2008 |
Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Cross-Sectional Studies; Diphosphonates; Follow-Up Studies; Germany; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Prevalence; Prognosis; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Zoledronic Acid | 2008 |
Bisphosphonate-related osteonecrosis of the jaws--report of 2 cases and strategies on prevention and management.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Hyperbaric Oxygenation; Imidazoles; Jaw Diseases; Osteonecrosis; Osteoporosis; Tooth Extraction; Zoledronic Acid | 2008 |
Consequence of therapy discontinuation in bisphosphonate-associated osteonecrosis of the jaws.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents, Local; Bone Density Conservation Agents; Bone Neoplasms; Chlorhexidine; Debridement; Diphosphonates; Female; Humans; Hydrogen Peroxide; Imidazoles; Maxillary Diseases; Middle Aged; Mouthwashes; Multiple Myeloma; Oroantral Fistula; Osteonecrosis; Tooth Extraction; Zoledronic Acid | 2009 |
Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.
Topics: Academies and Institutes; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Dental Prophylaxis; Diphosphonates; Female; Humans; Imidazoles; Incidence; Italy; Jaw Diseases; Male; Middle Aged; Neoplasms; Osteonecrosis; Retrospective Studies; Young Adult; Zoledronic Acid | 2009 |
Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution.
Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Health Knowledge, Attitudes, Practice; Humans; Imidazoles; Incidence; Italy; Jaw Diseases; Male; Osteonecrosis; Pamidronate; Retrospective Studies; Risk Factors; Zoledronic Acid | 2008 |
Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Dental Prophylaxis; Diphosphonates; Female; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pyrazines; Retrospective Studies; Thalidomide; Young Adult; Zoledronic Acid | 2009 |
Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Jaw; Jaw Neoplasms; Male; Mandible; Maxilla; Osteonecrosis; Pamidronate; Retrospective Studies; Risk Factors; Treatment Outcome; Zoledronic Acid | 2008 |
Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Bone Diseases, Metabolic; Dexamethasone; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Injections, Intravenous; Jaw Diseases; Mandibular Diseases; Maxillary Diseases; Oral Ulcer; Osteonecrosis; Prospective Studies; Rats; Rats, Sprague-Dawley; Zoledronic Acid | 2009 |
Re: Christian Walter, Bilal Al-Nawas, Knut A. Grötz, et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008;54:1066-72.
Topics: Bone Density Conservation Agents; Diphosphonates; Disease Progression; Humans; Imidazoles; Jaw Diseases; Male; Osteonecrosis; Prevalence; Prostatic Neoplasms; Risk Factors; Zoledronic Acid | 2009 |
Dental and periodontal history of oncologic patients on parenteral bisphosphonates with or without osteonecrosis of the jaws: a pilot study.
Topics: Aged; Aged, 80 and over; Alveolar Bone Loss; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; DMF Index; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Neoplasms; Osteonecrosis; Periodontal Index; Pilot Projects; Retrospective Studies; Risk Factors; Stomatitis, Denture; Tooth Extraction; Zoledronic Acid | 2008 |
Re: Christan Walter, Bilal Al-Nawas, Knut A. Grötz, et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008;54:1066-72.
Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Osteonecrosis; Prevalence; Prostatic Neoplasms; Risk Factors; Zoledronic Acid | 2009 |
Radiology quiz case. Osteonecrosis of the jaw: aminobisphosphonate epidemic.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Disease Outbreaks; Humans; Image Processing, Computer-Assisted; Imidazoles; Male; Mandibular Diseases; Multiple Myeloma; Osteonecrosis; Radiography, Panoramic; Reoperation; Tomography, Spiral Computed; Zoledronic Acid | 2008 |
Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis.
Topics: Apoptosis; Blotting, Western; Bone Density Conservation Agents; Caspase 3; Caspase 9; Cell Line; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Epithelial Cells; Fibroblasts; Gene Expression; Gene Expression Profiling; Gingiva; Humans; Imidazoles; In Situ Nick-End Labeling; Jaw Diseases; Mouth Mucosa; Oligonucleotide Array Sequence Analysis; Osteonecrosis; RNA Interference; RNA, Small Interfering; Zoledronic Acid | 2009 |
Comment on: Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Breast Neoplasms; Dexamethasone; Diphosphonates; Disease Models, Animal; Female; Glucocorticoids; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Rats; Tooth Extraction; Zoledronic Acid | 2009 |
Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene.
Topics: Alendronate; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Collagen Type I; Cysteine Endopeptidases; Diphosphonates; Female; Humans; Imidazoles; Male; Mandibular Diseases; Matrix Metalloproteinase 2; Maxillary Diseases; Osteocalcin; Osteonecrosis; Parathyroid Hormone; Peptides; Vitamin D; Zoledronic Acid | 2009 |
Clinical characterization might help in preventing osteonecrosis of the jaw.
Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Zoledronic Acid | 2008 |
Positron-emission tomography imaging in the diagnosis of bisphosphonate-related osteonecrosis of the jaw.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Imidazoles; Jaw Diseases; Male; Osteonecrosis; Positron-Emission Tomography; Radiopharmaceuticals; Zoledronic Acid | 2009 |
[Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma].
Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw; Multiple Myeloma; Oral Hygiene; Osteonecrosis; Pamidronate; Risk Factors; Zoledronic Acid | 2009 |
Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies.
Topics: Aged; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Genital Neoplasms, Female; Humans; Imidazoles; Incidence; Jaw; Middle Aged; Osteonecrosis; Risk Factors; Zoledronic Acid | 2009 |
Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: a Belgian case series.
Topics: Adult; Aged; Aged, 80 and over; Belgium; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Retrospective Studies; Risk Factors; Zoledronic Acid | 2009 |
Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile?
Topics: Angiogenesis Inhibitors; Diphosphonates; Humans; Imidazoles; Indoles; Jaw Diseases; Osteonecrosis; Pyrroles; Sunitinib; Zoledronic Acid | 2009 |
The role of inferior alveolar nerve involvement in bisphosphonate-related osteonecrosis of the jaw.
Topics: Aged; Anti-Bacterial Agents; Bone Density Conservation Agents; Diphosphonates; Female; Gingivitis, Necrotizing Ulcerative; Humans; Imidazoles; Male; Mandibular Diseases; Mandibular Nerve; Middle Aged; Osteonecrosis; Somatosensory Disorders; Zoledronic Acid | 2009 |
Recurrent low-energy femoral shaft fractures and osteonecrosis of the jaw in a case of multiple myeloma treated with bisphosphonates.
Topics: Bone Density Conservation Agents; Cross Infection; Diphosphonates; Escherichia coli Infections; Fatal Outcome; Femoral Fractures; Fractures, Spontaneous; Humans; Imidazoles; Injections, Intravenous; Male; Maxillary Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Osteopetrosis; Recurrence; Zoledronic Acid | 2009 |
Bisphosphonate-related osteonecrosis of the skull base.
Topics: Bone Density Conservation Agents; Diagnosis, Differential; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Neurosurgical Procedures; Osteonecrosis; Skull Base; Tomography, X-Ray Computed; Zoledronic Acid | 2009 |
Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Resorption; Dexamethasone; Diphosphonates; Female; Humans; Imidazoles; Jaw; Male; Middle Aged; Multiple Myeloma; Necrosis; Osteoclasts; Osteonecrosis; Thalidomide; Zoledronic Acid | 2009 |
Bisphosphonate-associated osteonecrosis of the jaws: the limits of a conservative approach.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Zoledronic Acid | 2009 |
Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases.
Topics: Adenocarcinoma; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Neoplasm Staging; Osteonecrosis; Pancreatic Neoplasms; Zoledronic Acid | 2009 |
Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Angiogenesis Inhibitors; Anti-Bacterial Agents; Anti-Inflammatory Agents; Bone Density Conservation Agents; Diabetes Mellitus, Type 2; Diphosphonates; Female; Follow-Up Studies; Glucocorticoids; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Minimally Invasive Surgical Procedures; Oral Surgical Procedures; Osteonecrosis; Pamidronate; Risk Factors; Smoking; Time Factors; Treatment Outcome; Wound Healing; Zoledronic Acid | 2009 |
Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Pamidronate; Treatment Outcome; Zoledronic Acid | 2009 |
Pathological fractures in patients caused by bisphosphonate-related osteonecrosis of the jaws: report of 3 cases.
Topics: Administration, Oral; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Follow-Up Studies; Fracture Fixation, Internal; Fractures, Spontaneous; Humans; Imidazoles; Injections, Intravenous; Male; Mandibular Diseases; Mandibular Fractures; Middle Aged; Osteonecrosis; Palliative Care; Tooth Extraction; Zoledronic Acid | 2009 |
Paget's disease of bone and osteonecrosis.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Dry Socket; Female; Humans; Hypercementosis; Imidazoles; Injections, Intravenous; Maxillary Diseases; Osteitis Deformans; Osteonecrosis; Pamidronate; Skull; Tooth Extraction; Tooth Socket; Zoledronic Acid | 2009 |
[Osteonecrosis of the jaw].
Topics: Adult; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw; Male; Osteonecrosis; Zoledronic Acid | 2009 |
Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Early Diagnosis; Female; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Neoplasms; Osteonecrosis; Pamidronate; Radionuclide Imaging; Radiopharmaceuticals; Retrospective Studies; Technetium Compounds; Zoledronic Acid | 2009 |
Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Connective Tissue; Diphosphonates; Female; Humans; Imidazoles; Inflammation; Jaw; Jaw Diseases; Male; Mandibular Diseases; Maxillary Diseases; Microscopy, Electron, Scanning; Middle Aged; Osteomyelitis; Osteonecrosis; Osteoporosis; Osteoradionecrosis; Pamidronate; Time Factors; Zoledronic Acid | 2010 |
Zoledronic acid decreases bone formation without causing osteocyte death in mice.
Topics: Alveolar Process; Animals; Bone Density Conservation Agents; Cell Death; Cell Survival; Diphosphonates; Femur; Fluoresceins; Fluorescent Dyes; Imidazoles; L-Lactate Dehydrogenase; Male; Mandible; Maxilla; Mice; Mice, Inbred C57BL; Osteocytes; Osteogenesis; Osteonecrosis; Zoledronic Acid | 2009 |
Mandibular necrosis in beagle dogs treated with bisphosphonates.
Topics: Alendronate; Alveolar Process; Animals; Bone Density Conservation Agents; Bone Matrix; Bone Remodeling; Cell Death; Cell Survival; Coloring Agents; Diphosphonates; Disease Models, Animal; Dogs; Female; Haversian System; Imidazoles; L-Lactate Dehydrogenase; Mandibular Diseases; Osteocytes; Osteonecrosis; Ribs; Rosaniline Dyes; Time Factors; Zoledronic Acid | 2009 |
A novel bioassay model to determine clinically significant bisphosphonate levels.
Topics: Adult; Apoptosis; Biological Assay; Bone and Bones; Bone Density Conservation Agents; Cell Line; Cell Proliferation; Diphosphonates; Humans; Imidazoles; Mouth Mucosa; Osteonecrosis; Risk Factors; Saliva; Zoledronic Acid | 2009 |
Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Greece; Humans; Ibandronic Acid; Imidazoles; Incidence; Jaw Diseases; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Risk Factors; Zoledronic Acid | 2009 |
Bisphosphonate-related osteonecrosis of the jaw and left thumb.
Topics: Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Curettage; Diphosphonates; Female; Finger Phalanges; Humans; Imidazoles; Jaw Diseases; Middle Aged; Osteonecrosis; Osteotomy; Radiography; Thumb; Zoledronic Acid | 2009 |
Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice.
Topics: Animals; Bacterial Adhesion; Bacterial Physiological Phenomena; Bone Density Conservation Agents; Cell Movement; Cell Proliferation; Cells, Cultured; Dental Plaque; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Jaw Diseases; Male; Mice; Mice, Inbred Strains; Mouth Mucosa; Neovascularization, Physiologic; Osteogenesis; Osteonecrosis; Streptococcus mutans; Tooth Extraction; Tooth Socket; Wound Healing; Zoledronic Acid | 2010 |
Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Imidazoles; Jaw Diseases; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Retrospective Studies; Spinal Cord Compression; Time Factors; Treatment Outcome; Zoledronic Acid | 2009 |
Jaw bone changes in rats after treatment with zoledronate and pamidronate.
Topics: Animals; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Female; Femur; Imidazoles; Inflammation; Mandible; Osteonecrosis; Pamidronate; Rats; Rats, Sprague-Dawley; Single-Blind Method; Time Factors; Zoledronic Acid | 2010 |
[Maxillary osteonecrosis associated with the use of zoledronate: Presentation of three cases].
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Male; Maxillary Diseases; Middle Aged; Osteonecrosis; Zoledronic Acid | 2010 |
Scintigraphic evaluation of mandibular bone turnover in patients with solid tumors receiving zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Risk Factors; Tomography, Emission-Computed; Zoledronic Acid | 2010 |
Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Ear, External; Etidronic Acid; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Inflammation Mediators; Injections, Intraperitoneal; Injections, Subcutaneous; Interleukin-1; Male; Mice; Mice, Inbred BALB C; Necrosis; Osteonecrosis; Osteosclerosis; Pamidronate; Pravastatin; Radionuclide Imaging; Radiopharmaceuticals; Risedronic Acid; Technetium; Tibia; Time Factors; Zoledronic Acid | 2010 |
Bisphosphonate-induced osteonecrosis of the jaw 32 months after interruption of zoledronate in a patient with multiple myeloma.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Maxillary Diseases; Multiple Myeloma; Oroantral Fistula; Osteonecrosis; Zoledronic Acid | 2010 |
Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats.
Topics: Animals; Apoptosis; Diphosphonates; Disease Models, Animal; Femur; Gene Expression Regulation; Humans; Imidazoles; Inflammation; Jaw Diseases; Oligonucleotide Array Sequence Analysis; Osteoclasts; Osteogenesis; Osteonecrosis; Rats; Rats, Sprague-Dawley; Tooth Extraction; Vitamin D; Vitamin D Deficiency; Zoledronic Acid | 2010 |
Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice.
Topics: Animals; Cytokines; Dexamethasone; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Immunosuppressive Agents; Immunotherapy; Jaw Diseases; Mesenchymal Stem Cell Transplantation; Mice; Mice, Inbred C57BL; Mice, Nude; Osteonecrosis; T-Lymphocytes, Regulatory; Zoledronic Acid | 2010 |
A novel animal model to study non-spontaneous bisphosphonates osteonecrosis of jaw.
Topics: Animals; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Injections, Intravenous; Jaw Diseases; Maxillary Diseases; Osteonecrosis; Radionuclide Imaging; Rats; Rats, Wistar; Reproducibility of Results; Tooth Extraction; Zoledronic Acid | 2010 |
A clinico-pathologic correlation. Bisphosphonate-related osteonecrosis of the jaws.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diagnosis, Differential; Diphosphonates; Female; Humans; Imidazoles; Mandibular Diseases; Middle Aged; Osteonecrosis; Zoledronic Acid | 2010 |
Use of cone-beam computerized tomography for evaluation of bisphosphonate-associated osteonecrosis of the jaws.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Cone-Beam Computed Tomography; Diphosphonates; Dry Socket; Female; Humans; Imaging, Three-Dimensional; Imidazoles; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Oroantral Fistula; Osteonecrosis; Osteosclerosis; Pamidronate; Radiography, Dental, Digital; Radiography, Panoramic; Tooth Socket; Zoledronic Acid | 2010 |
Bisphosphonate-related osteonecrosis of the jaw combined with jaw metastasis of prostate adenocarcinoma: report of a case.
Topics: Adenocarcinoma; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Male; Mandibular Diseases; Mandibular Neoplasms; Middle Aged; Osteonecrosis; Prostatic Neoplasms; Zoledronic Acid | 2010 |
Osteonecrosis of the jaw (ONJ) risk in breast cancer patients after zoledronic acid treatment.
Topics: Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw; Osteonecrosis; Zoledronic Acid | 2010 |
Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study.
Topics: Aged; Alcohol Drinking; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Chronic Disease; Clindamycin; Cohort Studies; Combined Modality Therapy; Debridement; Diphosphonates; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Imidazoles; Jaw Diseases; Male; Oral Fistula; Osteonecrosis; Pamidronate; Penicillins; Prospective Studies; Remission Induction; Risk Factors; Smoking; Tooth Extraction; Treatment Outcome; Wound Healing; Zoledronic Acid | 2010 |
Compromised osseous healing of dental extraction sites in zoledronic acid-treated dogs.
Topics: Animals; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Dogs; Female; Imidazoles; Jaw Diseases; Osteonecrosis; Tomography, X-Ray Computed; Tooth Extraction; Treatment Outcome; Wound Healing; Zoledronic Acid | 2011 |
Bisphosphonates cause osteonecrosis of the jaw-like disease in mice.
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Remodeling; Dexamethasone; Diphosphonates; Docetaxel; Humans; Imidazoles; Jaw Diseases; Mandible; Mice; Mice, Inbred C57BL; Neovascularization, Physiologic; Osteocytes; Osteonecrosis; Taxoids; Zoledronic Acid | 2010 |
Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Diphosphonates; Drug Synergism; Humans; Imidazoles; Indoles; Infusions, Intravenous; Kidney Neoplasms; Male; Mandibular Diseases; Middle Aged; Neoplasm Staging; Osteonecrosis; Pyrroles; Sacrum; Spinal Neoplasms; Sunitinib; Zoledronic Acid | 2010 |
Association between bisphosphonates and jaw osteonecrosis: a study in Wistar rats.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Drug Therapy, Combination; Imidazoles; Jaw; Osteonecrosis; Random Allocation; Rats; Rats, Wistar; Tooth Extraction; Zoledronic Acid | 2011 |
Bisphosphonates and atypical femoral fractures.
Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Femoral Fractures; Hip Fractures; Humans; Imidazoles; Osteonecrosis; Risk Factors; Zoledronic Acid | 2010 |
Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism.
Topics: Bone Density Conservation Agents; Cell Line; Cell Movement; Cell Proliferation; Cell Shape; Cell Survival; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Fluorescent Dyes; Humans; Hydrogen-Ion Concentration; Ibandronic Acid; Imidazoles; Jaw Diseases; Mesenchymal Stem Cells; Osteonecrosis; Time Factors; Zoledronic Acid | 2010 |
Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Debridement; Diphosphonates; Doxycycline; Female; Fluorescence; Fluorescent Dyes; Follow-Up Studies; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Pilot Projects; Prospective Studies; Surgical Flaps; Surgical Wound Dehiscence; Treatment Outcome; Wound Healing; Zoledronic Acid | 2011 |
Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Jaw; Male; Osteonecrosis; Pamidronate; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid | 2010 |
Chronic indurated gingival ulceration. Bisphosphonate-related osteonecrosis of the jaw (BRONJ).
Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Male; Mandibular Diseases; Middle Aged; Oral Ulcer; Osteonecrosis; Zoledronic Acid | 2010 |
Osteonecrosis of the maxilla associated with the use of bisphosphonates.
Topics: Diphosphonates; Humans; Imidazoles; Male; Maxilla; Middle Aged; Orbital Cellulitis; Osteonecrosis; Zoledronic Acid | 2010 |
Bisphosphonate-associated osteonecrosis of the jaws: surgical treatment with ErCrYSGG-laser. Case report.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Disease Progression; Female; Follow-Up Studies; Humans; Imidazoles; Jaw Diseases; Laser Therapy; Lasers, Solid-State; Low-Level Light Therapy; Mandibular Diseases; Middle Aged; Osteonecrosis; Photochemotherapy; Surgical Wound Dehiscence; Wound Healing; Zoledronic Acid | 2010 |
Management of osteonecrosis of the jaws in patients with history of bisphosphonates therapy.
Topics: Absorbable Implants; Aged; Anti-Bacterial Agents; Bone Density Conservation Agents; Cephalexin; Combined Modality Therapy; Debridement; Diphosphonates; Female; Follow-Up Studies; Humans; Hyperbaric Oxygenation; Imidazoles; Maxillary Diseases; Membranes, Artificial; Osteonecrosis; Osteosclerosis; Patient Care Team; Platelet-Rich Plasma; Treatment Outcome; Wound Healing; Zoledronic Acid | 2010 |
Effects of short-term zoledronic acid treatment on bone remodeling and healing at surgical sites in the maxilla and mandible of aged dogs.
Topics: Age Factors; Alveolar Process; Animals; Bicuspid; Bone Density Conservation Agents; Bone Remodeling; Dental Implantation, Endosseous; Diphosphonates; Dogs; Femur; Fluoresceins; Fluorescent Dyes; Imidazoles; L-Lactate Dehydrogenase; Male; Mandible; Mandibular Diseases; Maxilla; Maxillary Diseases; Models, Animal; Orthodontic Anchorage Procedures; Osteogenesis; Osteonecrosis; Random Allocation; Ribs; Tooth Extraction; Wound Healing; Zoledronic Acid | 2011 |
Bisphosphonate effects on the behaviour of oral epithelial cells and oral fibroblasts.
Topics: Apoptosis; Cell Line; Cell Movement; Cell Proliferation; Collagen; Diphosphonates; Down-Regulation; Epithelial Cells; Fibroblasts; Humans; Imidazoles; Jaw Diseases; Mouth Mucosa; Osteonecrosis; Reverse Transcriptase Polymerase Chain Reaction; Staining and Labeling; Tooth Extraction; Wound Healing; Zoledronic Acid | 2011 |
Effect of zoledronate on oral wound healing in rats.
Topics: Animals; Bone Marrow; Diphosphonates; Gene Expression Regulation; Gingiva; Homeostasis; Imidazoles; Matrix Metalloproteinase 13; Osteonecrosis; Platelet Endothelial Cell Adhesion Molecule-1; Rats; Rats, Sprague-Dawley; Vacuolar Proton-Translocating ATPases; Vascular Endothelial Growth Factor A; Wound Healing; Zoledronic Acid | 2011 |
Bisphosphonate-related osteonecrosis of the maxilla and sinusitis maxillaris.
Topics: Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bone Density Conservation Agents; Carcinoma; Chronic Disease; Debridement; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Injections, Intravenous; Male; Maxillary Diseases; Maxillary Sinusitis; Middle Aged; Osteonecrosis; Osteoporosis; Osteotomy; Recurrence; Risk Factors; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2011 |
Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Gene Frequency; Genetic Predisposition to Disease; Geranyltranstransferase; Humans; Imidazoles; Italy; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Pharmacogenetics; Polymorphism, Single Nucleotide; Retrospective Studies; White People; Zoledronic Acid | 2011 |
Rubber dam clamp trauma during endodontic treatment: a risk factor of bisphosphonate-related osteonecrosis of the jaw?
Topics: Bone Density Conservation Agents; Dental Caries; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Middle Aged; Osteonecrosis; Risk Factors; Root Canal Therapy; Rubber Dams; Zoledronic Acid | 2011 |
Vascular endothelial growth factor genetic polymorphisms and haplotypes in female patients with bisphosphonate-related osteonecrosis of the jaws.
Topics: Bone Density Conservation Agents; Breast Neoplasms; Case-Control Studies; Chi-Square Distribution; Diphosphonates; Female; Haplotypes; Humans; Imidazoles; Jaw Diseases; Multiple Myeloma; Odds Ratio; Osteonecrosis; Polymorphism, Single Nucleotide; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2011 |
Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): A retrospective analysis of 567 cases in an Italian multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Italy; Jaw Diseases; Male; Middle Aged; Orthognathic Surgical Procedures; Osteonecrosis; Retrospective Studies; Risk Factors; Zoledronic Acid | 2011 |
Preventive protocol for tooth extractions in patients treated with zoledronate: a case series.
Topics: Antibiotic Prophylaxis; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Middle Aged; Osteonecrosis; Radiography, Panoramic; Tooth Extraction; Zoledronic Acid | 2011 |
Msx-1 is suppressed in bisphosphonate-exposed jaw bone analysis of bone turnover-related cell signalling after bisphosphonate treatment.
Topics: Alkaline Phosphatase; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Bone Morphogenetic Protein 4; Bone Remodeling; Cell Count; Diphosphonates; Fibroblasts; Humans; Imidazoles; Immunohistochemistry; Jaw Diseases; MSX1 Transcription Factor; Osteoblasts; Osteocytes; Osteonecrosis; Osteopetrosis; Pamidronate; RANK Ligand; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Zoledronic Acid | 2011 |
Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw.
Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Bone Density Conservation Agents; Cohort Studies; Collagen Type I; Collagen Type I, alpha 1 Chain; Cytochrome P-450 CYP2C8; Diphosphonates; Female; Gene Frequency; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Matrix Metalloproteinase 2; Middle Aged; Multiple Myeloma; Osteonecrosis; Osteopontin; Osteoprotegerin; Pamidronate; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Receptor Activator of Nuclear Factor-kappa B; Risk Factors; Smoking; Time Factors; Tumor Necrosis Factor-alpha; Zoledronic Acid | 2011 |
Osteonecrosis of the jaw.
Topics: Biomarkers; Bone Density Conservation Agents; Collagen Type I; Dental Care; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Peptides; Risk Factors; Zoledronic Acid | 2011 |
More about osteonecrosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Denosumab; Dental Care; Diphosphonates; Drug Interactions; Humans; Imidazoles; Jaw Diseases; Oral Hygiene; Osteonecrosis; RANK Ligand; Risk Factors; Zoledronic Acid | 2011 |
Denosumab for bone metastases from breast cancer: a new therapy option?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Kidney; Osteonecrosis; RANK Ligand; Zoledronic Acid | 2011 |
[Prosthetic rehabilitation after osteonecrosis of the jaws due to histiocytosis X and treatment with bisphosphonates apropos of a case].
Topics: Adult; Alendronate; Bone Density Conservation Agents; Denture Design; Denture, Partial, Fixed; Denture, Partial, Temporary; Diphosphonates; Female; Histiocytosis, Langerhans-Cell; Humans; Imidazoles; Jaw, Edentulous, Partially; Mandibular Diseases; Osteonecrosis; Pamidronate; Risk Factors; Tooth Extraction; Zoledronic Acid | 2010 |
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Gene Frequency; Genetic Predisposition to Disease; Humans; Imidazoles; Jaw Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Polymorphism, Single Nucleotide; PPAR gamma; Zoledronic Acid | 2011 |
Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Collagen Type I; Dental Care; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Jaw Diseases; Lung Neoplasms; Male; Middle Aged; Osteonecrosis; Peptides; Periodontal Diseases; Radiography, Panoramic; Risk Factors; Tooth Extraction; Zoledronic Acid | 2011 |
Osteonecrosis of the jaw after zoledronic acid and denosumab treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Incidence; Jaw Diseases; Osteonecrosis; RANK Ligand; Zoledronic Acid | 2011 |
Bisphosphonates inhibit expression of p63 by oral keratinocytes.
Topics: Adult Stem Cells; Analysis of Variance; Bone Density Conservation Agents; Case-Control Studies; Cell Line, Transformed; Diphosphonates; Gene Expression; Gene Knockdown Techniques; Humans; Imidazoles; Jaw Diseases; Keratinocytes; Membrane Proteins; Mevalonic Acid; Osteonecrosis; RNA, Small Interfering; Tissue Culture Techniques; Wound Healing; Zoledronic Acid | 2011 |
Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents, Local; Bone Density Conservation Agents; Cariostatic Agents; Chlorhexidine; Dental Prophylaxis; Diphosphonates; Female; Fluorides; Follow-Up Studies; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Longitudinal Studies; Male; Middle Aged; Neoplasms; Oral Hygiene; Osteonecrosis; Pain Measurement; Pamidronate; Prospective Studies; Treatment Outcome; Zoledronic Acid | 2011 |
Differential impairment of vascularization and angiogenesis in bisphosphonate-associated osteonecrosis of the jaw-related mucoperiosteal tissue.
Topics: Alkaline Phosphatase; Alveolar Process; Antigens, CD; Bone Density Conservation Agents; Capillaries; Coloring Agents; Connective Tissue; Diphosphonates; Endoglin; Endothelial Cells; Endothelium, Vascular; Humans; Image Processing, Computer-Assisted; Imidazoles; Immunohistochemistry; Jaw Diseases; Mouth Mucosa; Neovascularization, Physiologic; Osteonecrosis; Periosteum; Platelet Endothelial Cell Adhesion Molecule-1; Receptors, Cell Surface; Zoledronic Acid | 2011 |
Rubber dam clamp trauma, root canal therapy, and osteonecrosis of the jaw.
Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Root Canal Therapy; Rubber Dams; Zoledronic Acid | 2011 |
Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.
Topics: Adult; Aged; Angiogenesis Inhibitors; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Jaw Diseases; Middle Aged; Neoplasm Metastasis; Osteonecrosis; Pamidronate; Retrospective Studies; Survival Rate; Treatment Outcome; Zoledronic Acid | 2011 |
Further analyses of the Myeloma IX Study.
Topics: Bone Density Conservation Agents; Clodronic Acid; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Osteonecrosis; Thrombosis; Zoledronic Acid | 2011 |
Bisphosphonate-associated osteonecrosis of the jaw: a six-year history of a case.
Topics: Bone Density Conservation Agents; Debridement; Diphosphonates; Disease Progression; Follow-Up Studies; Humans; Imidazoles; Immunoglobulin kappa-Chains; Male; Mandibular Diseases; Mandibular Neoplasms; Middle Aged; Multiple Myeloma; Osteonecrosis; Recurrence; Zoledronic Acid | 2011 |
[Inflammation of the jaws during treatment with bisphosphonates].
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Drug Approval; Female; Humans; Imidazoles; Infusions, Intravenous; Jaw Diseases; Opportunistic Infections; Osteomyelitis; Osteonecrosis; Osteoporosis; Pamidronate; Practice Guidelines as Topic; Risk Factors; Zoledronic Acid | 2011 |
Lip ulceration associated with intravenous administration of zoledronic acid: report of a case.
Topics: Analgesics; Antidepressive Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Lip Diseases; Middle Aged; Osteonecrosis; Ulcer; Zoledronic Acid | 2012 |
Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients.
Topics: Adult; Aged; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Neoplasms; Osteonecrosis; Risk Factors; Zoledronic Acid | 2011 |
Site specific effects of zoledronic acid during tibial and mandibular fracture repair.
Topics: Animals; Bone Density Conservation Agents; Bone Remodeling; Cartilage; Diphosphonates; Fracture Healing; Imidazoles; Male; Mandibular Fractures; Mice; Mice, Inbred C57BL; Osteonecrosis; Regeneration; Tibial Fractures; Zoledronic Acid | 2012 |
Comparison of effects of clodronate and zoledronic acid on the repair of maxilla surgical wounds - histomorphometric, receptor activator of nuclear factor-kB ligand, osteoprotegerin, von Willebrand factor, and caspase-3 evaluation.
Topics: Animals; Bacterial Load; Bone Density Conservation Agents; Caspase 3; Clodronic Acid; Connective Tissue; Diphosphonates; Epithelium; Female; Imidazoles; Maxilla; Maxillary Diseases; Mouth Mucosa; Osteonecrosis; Osteoprotegerin; RANK Ligand; Rats; Rats, Wistar; Tooth Extraction; Tooth Socket; von Willebrand Factor; Wound Healing; Zoledronic Acid | 2012 |
A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Incidence; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Neoplasm Staging; Neoplasms; Osteonecrosis; Pamidronate; Prognosis; Retrospective Studies; Risk Factors; Survival Rate; Zoledronic Acid | 2012 |
Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer treated using zoledronic acid and docetaxel.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Docetaxel; Drug Therapy, Combination; Humans; Imidazoles; Incidence; Japan; Jaw Neoplasms; Leukopenia; Male; Middle Aged; Osteonecrosis; Prognosis; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Taxoids; Zoledronic Acid | 2012 |
Early appearance of osteonecrosis of the jaw after zoledronic acid in a patient with a long history of taking oral bisphosphonates.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Zoledronic Acid | 2012 |
Avascular necrosis of the proximal carpal row of the wrist. A possible complication of bisphosphonate administration.
Topics: Bone Density Conservation Agents; Carpal Bones; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Osteonecrosis; Osteoporosis; Risk Factors; Treatment Outcome; Wrist; Zoledronic Acid | 2012 |
Home-based zoledronic acid infusion therapy in patients with solid tumours: compliance and patient-nurse satisfaction.
Topics: Adult; Aged; Aged, 80 and over; Attitude of Health Personnel; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Feasibility Studies; Female; Fractures, Bone; Home Infusion Therapy; Humans; Imidazoles; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Nurses, Community Health; Osteonecrosis; Patient Compliance; Patient Satisfaction; Physicians; Prospective Studies; Prostatic Neoplasms; Zoledronic Acid | 2013 |
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.
Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteoclasts; Osteocytes; Osteonecrosis; Pamidronate; Zoledronic Acid | 2003 |
Avascular necrosis of the jaws: risk factors in metastatic cancer patients.
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Pamidronate; Risk Factors; Zoledronic Acid | 2003 |
Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats.
Topics: Absorptiometry, Photon; Age Factors; Animals; Bone Density; Bone Development; Diphosphonates; Female; Femur Head; Imidazoles; Osteonecrosis; Rats; Rats, Wistar; Wounds and Injuries; Zoledronic Acid | 2003 |
Bisphosphonates and avascular necrosis of the jaws.
Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Pamidronate; Tooth Extraction; Zoledronic Acid | 2003 |
Intravenous bisphosphonates and osteonecrosis.
Topics: Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Interdisciplinary Communication; Jaw Diseases; Osteolysis; Osteonecrosis; Pamidronate; Zoledronic Acid | 2004 |
Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy.
Topics: Aged; Bone Density Conservation Agents; Debridement; Diphosphonates; Female; Humans; Imidazoles; Maxillary Diseases; Osteonecrosis; Tooth Extraction; Zoledronic Acid | 2005 |
Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma.
Topics: Aged; Diphosphonates; Humans; Imidazoles; Jaw; Male; Multiple Myeloma; Osteonecrosis; Zoledronic Acid | 2005 |
[Rapid drug information].
Topics: Adverse Drug Reaction Reporting Systems; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Information Services; Germany; Humans; Imidazoles; Jaw Diseases; Multiple Myeloma; Osteonecrosis; Osteoporosis; Pamidronate; Risk Assessment; Zoledronic Acid | 2005 |
Special precautions.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Diphosphonates; Fatal Outcome; Female; Humans; Imidazoles; Maxillary Diseases; Osteonecrosis; Zoledronic Acid | 2005 |
Bisphosphonates, cancer, and osteonecrosis--a single practice experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Debridement; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Infusions, Intravenous; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Neoplasms; Osteonecrosis; Pamidronate; Zoledronic Acid | 2005 |
Bisphosphonates, as a new cause of drug-induced jaw osteonecrosis: an update.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Jaw Diseases; Osteonecrosis; Osteoporosis; Pamidronate; Zoledronic Acid | 2005 |
Osteonecrosis of the jaw and bisphosphonates.
Topics: Breast Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Multiple Myeloma; Osteonecrosis; Pamidronate; Risk Factors; Zoledronic Acid | 2005 |
Osteonecrosis of the jaw and bisphosphonates.
Topics: Alendronate; Animals; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Osteoporosis; Pamidronate; Zoledronic Acid | 2005 |
Osteonecrosis of the jaw and bisphosphonates.
Topics: Breast Neoplasms; Dental Care; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Multiple Myeloma; Osteonecrosis; Risk Factors; Zoledronic Acid | 2005 |
Studies in osteonecrosis.
Topics: Antineoplastic Agents; Diphosphonates; Humans; Imidazoles; Osteonecrosis; Pamidronate; Zoledronic Acid | 2005 |
Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Osteonecrosis; Pamidronate; Zoledronic Acid | 2005 |
Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report.
Topics: Aged; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neoplasms; Curettage; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Mandibular Diseases; Maxillary Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Recurrence; Zoledronic Acid | 2005 |
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
Topics: Abscess; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Dental Caries; Dexamethasone; Diphosphonates; Drug Interactions; Female; Humans; Hyperostosis; Imidazoles; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Osteopetrosis; Osteoporosis; Pamidronate; Periodontitis; Prostatic Neoplasms; Risk Factors; Tooth Extraction; Zoledronic Acid | 2005 |
Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Mandibular Diseases; Maxillary Diseases; Multiple Myeloma; Osteomyelitis; Osteonecrosis; Zoledronic Acid | 2005 |
Bisphosphonate-induced osteonecrosis of the jaw requires early detection and intervention.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Osteonecrosis; Time Factors; Tooth Extraction; Zoledronic Acid | 2005 |
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Follow-Up Studies; Greece; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prospective Studies; Prostatic Neoplasms; Risk Factors; Time Factors; Treatment Failure; Zoledronic Acid | 2005 |
Important drug precaution for dental health professionals with patients being treated for cancer.
Topics: Bone Density Conservation Agents; Contraindications; Dental Care; Diphosphonates; Humans; Imidazoles; Neoplasms; Osteonecrosis; Zoledronic Acid | 2005 |
[Bisphosphonates-related jaw osteonecrosis].
Topics: Adolescent; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Pamidronate; Radiography, Panoramic; Radionuclide Imaging; Time Factors; Tomography, X-Ray Computed; Zoledronic Acid | 2005 |
Consumer groups look to improve adverse event reporting systems.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Bone Density Conservation Agents; Consumer Behavior; Diphosphonates; Drug Approval; Humans; Imidazoles; Multiple Myeloma; Osteonecrosis; Pamidronate; Product Surveillance, Postmarketing; United States; United States Food and Drug Administration; Zoledronic Acid | 2005 |
Bisphosphonate-associated osteonecrosis of the jaws: a review of current knowledge.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Mandible; Mandibular Diseases; Osteonecrosis; Radiography; Tooth Extraction; Wound Healing; Zoledronic Acid | 2005 |
Osteonecrosis of the jaws and bisphosphonates. Report of three cases.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcemia; Imidazoles; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Tooth Extraction; Zoledronic Acid | 2006 |
[Osteonecrosis of the jaws as a possible adverse effect of the use of bisphosphonates].
Topics: Aged; Alendronate; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Mouth Diseases; Osteonecrosis; Osteoporosis, Postmenopausal; Pamidronate; Plasmacytoma; Radiography, Panoramic; Risk Factors; Zoledronic Acid | 2005 |
By the way, doctor. I've heard that taking Fosamax for a long time causes the jawbone to deteriorate. Do you know anything about this?
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Osteoclasts; Osteonecrosis; Pamidronate; Zoledronic Acid | 2005 |
Jaw complications in breast and prostate cancer patients treated with zoledronic acid.
Topics: Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Osteonecrosis; Prostatic Neoplasms; Zoledronic Acid | 2006 |
Case 2. Osteonecrosis of the jaws associated with bisphosphonate therapy.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Hyperbaric Oxygenation; Imidazoles; Jaw; Kidney Neoplasms; Male; Osteonecrosis; Pain; Zoledronic Acid | 2006 |
Association of osteonecrosis of the jaws and bisphosphonate pharmacotherapy: dental implications.
Topics: Adenocarcinoma; Aged, 80 and over; Bone Density Conservation Agents; Carcinoma; Diabetes Mellitus, Type 2; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Patient Care Planning; Tooth Extraction; Zoledronic Acid | 2006 |
Relationship between periodontal disease and systemic diseases.
Topics: Alendronate; Bone Density Conservation Agents; Contraindications; Dental Implantation, Endosseous; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Jaw Diseases; Osteonecrosis; Pamidronate; Zoledronic Acid | 2006 |
Oral post-surgical complications following the administration of bisphosphonates given for osteopenia related to malignancy.
Topics: Aged; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Osteonecrosis; Periodontitis; Zoledronic Acid | 2006 |
Expert panel recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaws.
Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Zoledronic Acid | 2005 |
The buzz about bisphosphonates.
Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Pamidronate; Zoledronic Acid | 2005 |
Jaw complications associated with bisphosphonate use in patients with plasma cell dyscrasias.
Topics: Adult; Aged; Aged, 80 and over; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteomyelitis; Osteonecrosis; Pamidronate; Paraproteinemias; Zoledronic Acid | 2006 |
Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Retrospective Studies; Tooth Extraction; Zoledronic Acid | 2006 |
[Bisphosphonates and osteonecrosis of the jaws in patients with myelomatosis].
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Pamidronate; Zoledronic Acid | 2006 |
Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Radiography, Panoramic; Radionuclide Imaging; Retrospective Studies; Technetium Tc 99m Medronate; Tomography, X-Ray Computed; Zoledronic Acid | 2006 |
Drug induced osteonecrosis of the jaws.
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents, Local; Bone Density; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Osteoclasts; Osteomyelitis; Osteonecrosis; Pamidronate; Splints; Zoledronic Acid | 2006 |
Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Oral Surgical Procedures; Osteonecrosis; Osteoporosis; Pamidronate; Zoledronic Acid | 2006 |
Bisphosphonates: case report of nonsurgical periodontal therapy and osteochemonecrosis.
Topics: Alveolar Bone Loss; Bone Density Conservation Agents; Dental Scaling; Diphosphonates; Humans; Imidazoles; Male; Mandibular Diseases; Middle Aged; Oral Fistula; Osteonecrosis; Periodontitis; Root Planing; Tooth Extraction; Tooth Socket; Zoledronic Acid | 2006 |
Zoledronic acid for the treatment of thalassemia-induced osteonecrosis.
Topics: beta-Thalassemia; Diphosphonates; Dose-Response Relationship, Drug; Humans; Imidazoles; Osteonecrosis; Osteoporosis; Zoledronic Acid | 2006 |
Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients.
Topics: Adult; Aged; Biopsy; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Follow-Up Studies; Histiocytosis, Langerhans-Cell; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Magnetic Resonance Imaging; Male; Mandible; Mandibular Diseases; Maxilla; Maxillary Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Radiography, Panoramic; Radionuclide Imaging; Retrospective Studies; Risk Factors; Time Factors; Tomography, X-Ray Computed; Zoledronic Acid | 2006 |
Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Creatinine; Diphosphonates; Drug Monitoring; Female; Follow-Up Studies; Humans; Imidazoles; Jaw Diseases; Kidney Diseases; Male; Middle Aged; Osteonecrosis; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Zoledronic Acid | 2007 |
Jaw osteonecrosis associated with bisphosphonates.
Topics: Aged; Diphosphonates; Fatal Outcome; Humans; Imidazoles; Male; Maxilla; Multiple Myeloma; Osteonecrosis; Radiography; Zoledronic Acid | 2006 |
[Osteonecrosis of the jaw in patients with multiple myeloma during and after treatment with zoledronic acid].
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Risk Factors; Zoledronic Acid | 2006 |
Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer.
Topics: Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Mandible; Maxilla; Middle Aged; Multiple Myeloma; Necrosis; Osteonecrosis; Pamidronate; Tomography, X-Ray Computed; Zoledronic Acid | 2007 |
Osteonecrosis of the jaws in patients with bone metastasis receiving intravenous bisphosphonates. A rising concern.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Mastectomy; Middle Aged; Osteonecrosis; Radiotherapy; Zoledronic Acid | 2006 |
[Osteonecrosis associated with the use of biphosphonates: Case report].
Topics: Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Pamidronate; Zoledronic Acid | 2006 |
Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Antifungal Agents; Bone Density Conservation Agents; Bone Neoplasms; Chlorhexidine; Curettage; Diphosphonates; Female; Humans; Hydrogen Peroxide; Imidazoles; Jaw Diseases; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Mouthwashes; Multiple Myeloma; Osteonecrosis; Osteoporosis; Pamidronate; Radiography; Time Factors; Zoledronic Acid | 2006 |
Bisphosphonate-associated osteonecrosis of the jaws: a therapeutic dilemma.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Zoledronic Acid | 2007 |
I'm taking bisphosphonates for my osteoporosis, but I've heard it can cause a serious jaw condition. Is this something I should be concerned about?
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Pamidronate; Zoledronic Acid | 2006 |
Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder.
Topics: Adult; Aged; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Pamidronate; Risk Factors; Switzerland; Time Factors; Zoledronic Acid | 2007 |
Treatment of avascular osteonecrosis of the mandible in cancer patients with a history of bisphosphonate therapy by combining bone resection and autologous platelet-rich plasma: Report of 3 cases.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Mandibular Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Platelet-Rich Plasma; Tooth Extraction; Zoledronic Acid | 2007 |
Bisphosphonates and jaw osteonecrosis: the UAMS experience.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Bone Density Conservation Agents; Curettage; Dental Care; Diphosphonates; Female; Humans; Hyperbaric Oxygenation; Imidazoles; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Retrospective Studies; Time Factors; Treatment Outcome; Zoledronic Acid | 2007 |
[Osteonecrosis of the jawbone as a side effect of intravenous treatment with bisphosphonates].
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Male; Mandibular Diseases; Multiple Myeloma; Oral Hygiene; Osteonecrosis; Zoledronic Acid | 2007 |
A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma.
Topics: Aged; Diphosphonates; Drug Administration Schedule; Drug Evaluation; Female; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Retrospective Studies; Risk Factors; Zoledronic Acid | 2007 |
Bisphosphonate treatment as a cause of jaw osteonecrosis.
Topics: Anti-Bacterial Agents; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Tooth Extraction; Zoledronic Acid | 2007 |
Treatments for osteoporosis - looking beyond the HORIZON.
Topics: Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Fractures, Bone; Humans; Imidazoles; Osteonecrosis; Osteoporosis, Postmenopausal; Zoledronic Acid | 2007 |
Bisphosphonates and osteonecrosis of the jaw.
Topics: Bone Remodeling; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Neoplasms; Osteonecrosis; Osteoporosis; Pamidronate; Zoledronic Acid | 2007 |
Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Prostatic Neoplasms; Zoledronic Acid | 2007 |
Severe spontaneous cases of bisphosphonate-related osteonecrosis of the jaws.
Topics: Aged; Aged, 80 and over; Alveolar Process; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Mandibular Diseases; Maxillary Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Radiography; Severity of Illness Index; Zoledronic Acid | 2007 |
A novel case of bisphosphonate-related osteonecrosis of the torus palatinus in a patient with metastatic breast cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Exostoses; Female; Humans; Imidazoles; Maxilla; Middle Aged; Osteonecrosis; Palate, Hard; Zoledronic Acid | 2006 |
Orofacial pain - a presenting symptom of bisphosphonate associated osteonecrosis of the jaws.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents, Local; Bone Density Conservation Agents; Chlorhexidine; Diphosphonates; Facial Pain; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Osteoporosis, Postmenopausal; Tetracycline; Zoledronic Acid | 2007 |
Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Prostatic Neoplasms; Zoledronic Acid | 2007 |
Treating bisphosphonate osteonecrosis of the jaws: is there a role for resection and vascularized reconstruction?
Topics: Bone Density Conservation Agents; Bone Plates; Bone Transplantation; Breast Neoplasms; Carcinoma; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Mandibular Diseases; Middle Aged; Osteonecrosis; Pamidronate; Plastic Surgery Procedures; Surgical Flaps; Zoledronic Acid | 2007 |
Intravenous bisphosphonate-associated osteonecrosis of the jaw.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Mandibular Fractures; Multiple Myeloma; Osteonecrosis; Radiography; Zoledronic Acid | 2007 |
Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw; Male; Middle Aged; Multiple Myeloma; Orthognathic Surgical Procedures; Osteonecrosis; Osteoporosis; Pamidronate; Prospective Studies; Zoledronic Acid | 2008 |
Improvement of zoledronic-acid-induced jaw osteonecrosis with bortezomib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Doxorubicin; Female; Humans; Imidazoles; Mandibular Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Protease Inhibitors; Pyrazines; Tooth Extraction; Transplantation, Autologous; Vincristine; Zoledronic Acid | 2007 |
Possible delayed onset of osteonecrosis of the jaw in association with zoledronic acid.
Topics: Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Time Factors; Zoledronic Acid | 2007 |
Jaw avascular osteonecrosis after treatment of multiple myeloma with zoledronate.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Male; Mandibular Diseases; Multiple Myeloma; Osteonecrosis; Radiography, Panoramic; Zoledronic Acid | 2008 |
Zoledronate-related osteonecrosis of the mandible.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Mandibular Diseases; Middle Aged; Osteonecrosis; Tomography, Emission-Computed; Tomography, X-Ray Computed; Zoledronic Acid | 2008 |
Bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma.
Topics: Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Male; Mandibular Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Tooth Extraction; Wound Healing; Zoledronic Acid | 2008 |
Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?
Topics: Adolescent; Bone Density Conservation Agents; Child; Cohort Studies; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Oral Surgical Procedures; Osteonecrosis; Pamidronate; Zoledronic Acid | 2008 |
"Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Neoplasms; Oral Surgical Procedures; Osteonecrosis; Pamidronate; Retrospective Studies; Risk Factors; Surveys and Questionnaires; Zoledronic Acid | 2008 |
[Jaw fistulas in 75 years-old woman].
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Female; Fistula; Humans; Imidazoles; Mandibular Diseases; Osteonecrosis; Zoledronic Acid | 2008 |
Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw; Jaw Diseases; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Tomography, Spiral Computed; Tooth Extraction; Water; Zoledronic Acid | 2008 |
Case records of the Massachusetts General Hospital. Case 9-2008. A 65-year-old woman with a nonhealing ulcer of the jaw.
Topics: Aged; Diagnosis, Differential; Diphosphonates; Female; Gingiva; Gingival Diseases; Humans; Imidazoles; Mandible; Mandibular Diseases; Multiple Myeloma; Osteonecrosis; Precipitating Factors; Radiography; Tooth Extraction; Ulcer; Zoledronic Acid | 2008 |
Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study.
Topics: Age Factors; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Case-Control Studies; Confounding Factors, Epidemiologic; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Jaw Diseases; Logistic Models; Male; Multivariate Analysis; Neoplasms; Obesity; Osteonecrosis; Pamidronate; Risk Factors; Smoking; Zoledronic Acid | 2008 |
Osteonecrosis of the jaw.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Hip Fractures; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Osteoporosis, Postmenopausal; Pamidronate; Time Factors; Zoledronic Acid | 2008 |
Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates.
Topics: Aged; Biomarkers; Bone Density Conservation Agents; Bone Resorption; Case-Control Studies; Collagen Type I; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Zoledronic Acid | 2008 |
Osteonecrosis of the jaw.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Middle Aged; Osteonecrosis; Penicillin V; Risk Factors; Tooth Extraction; Zoledronic Acid | 2008 |
Bisphosphonates and osteonecrosis of the jaw: a case report.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Zoledronic Acid | 2008 |
Paget's disease and bisphosphonate-associated osteonecrosis of the jaws.
Topics: Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Male; Maxillary Diseases; Osteitis Deformans; Osteonecrosis; Pamidronate; Zoledronic Acid | 2008 |